STOCK TITAN

Cizzle Brands prices stock offering at US$5 a share

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Cizzle Brands Corp priced an offering of 3,030,000 common shares at US$5.00 per share, with a 45-day option for the underwriter to purchase up to 454,500 additional shares. Gross proceeds are expected to be approximately US$15.15 million before underwriting discounts, commissions and other estimated offering expenses, excluding any option exercise. Closing is expected on or about November 23, 2026, subject to customary conditions. The company plans to use net proceeds for partial repayment of indebtedness incurred to finance its acquisition of Flow Water Inc.’s beverage co-manufacturing business, factory capacity expansion and general corporate purposes; management will have broad discretion over their use.

The 1-for-25 common-share consolidation took effect November 20, 2026 and remains subject to Cboe Canada policies. Trading of post-consolidation shares on Nasdaq and Cboe Canada is expected to begin that day under CZZL. The company also intends to extend 36,419,635 warrants, on a pre-consolidation basis, from November 28, 2026 to November 28, 2027; disinterested shareholders approved the extension, which remains subject to Cboe Canada acceptance.

Filing Explained

If completed, the sale adds 3,030,000 shares to the expected 9,217,365 pre-offering base; closing remains conditional.

Cizzle Brands reports pricing 3,030,000 common shares at US$5.00 each and a signed underwriting agreement; closing is expected on or about November 23, 2026, subject to conditions, so the shares are not yet disclosed as issued. If completed, the issuance increases the share count and reduces existing holders’ percentage ownership absent offsetting changes; the company expects about 9,217,365 shares after the consolidation but before the offering and assuming no additional issuances.

An underwritten offering has a bank buy shares from the issuer for resale; here, the agreement makes purchase of the 3,030,000 firm shares subject to closing conditions, while the additional 454,500 shares are only an option. The agreement specifies a US$0.325 underwriting discount and a US$0.05 non-accountable expense allowance per share; proceeds to the company are US$4.675 per share before accountable expenses.

The attached lock-up form would restrict covered holders’ transfers and hedging until three months after closing, subject to exceptions; Schedule 4 identifies directors, officers, and holders of 5% or more as required to deliver lock-up agreements.

Firm shares 3,030,000 common shares Base offering; priced at US$5.00 per share
Public offering price US$5.00 per share Price per offered share
Expected gross proceeds Approximately US$15.15 million Before underwriting discounts, commissions and other estimated offering expenses; excludes option exercise
Over-allotment option Up to 454,500 common shares 45-day option to purchase additional shares
Consolidation ratio One post-consolidation share for every 25 pre-consolidation shares Effective November 20, 2026
Warrants intended for extension 36,419,635 warrants Pre-consolidation basis; proposed expiry extension from November 28, 2026 to November 28, 2027, subject to Cboe Canada acceptance
Warrant exercise price $0.40 per share Pre-consolidation basis, subject to adjustment under the warrant terms
Proceeds to the Company per Offered Share US$4.675 Before accountable expenses
Over-Allotment Option financial
"option to purchase up to 454,500 additional Common Shares"
An over-allotment option is a special agreement that allows underwriters to sell more shares than initially planned if demand is high. Think of it like a retailer offering extra units of a popular product to meet additional customer interest. This option helps ensure the full sale is completed and can also give investors extra shares if they want more.
Listed Issuer Financing Exemption regulatory
"the “Listed Issuer Financing Exemption”"
A listed issuer financing exemption is a regulatory allowance that lets a publicly traded company raise money by selling securities without preparing a full, formal prospectus when specific conditions are met. Think of it as a permitted shortcut with guardrails: it speeds access to capital while still requiring certain disclosures and limits, and it matters to investors because it can dilute existing holdings, change ownership stakes, and quickly affect share price and company funding prospects.
Consolidation technical
"one (1) post-consolidation common share for every twenty-five (25) pre-consolidation"
Consolidation is a period when a stock’s price moves within a relatively narrow range, reflecting a balance between buyers and sellers after a prior rise or fall. It matters to investors because it often signals a pause before the next meaningful move — like a coiled spring — and helps with timing trades, setting risk limits and deciding whether momentum will resume upward or reverse downward.
Underwriting Discount financial
"Underwriting Discount per Offered Share: US$0.325"
The underwriting discount is the fee that investment banks or broker-dealers keep when they buy securities from an issuer and resell them to the public; it’s the difference between the price paid to the company and the public offering price, shown per share or as a percentage. It matters to investors because it reduces the cash the company actually raises and is a cost built into the deal—like a sales commission—so a larger discount can mean higher issuance costs, tighter returns for new investors, and a signal about how much effort underwriters must expend to sell the offering.
Non-accountable Expense Allowance financial
"Non-accountable Expense Allowance per Offered Share: US$0.05"
aseptic filling technical
"additional Tetra Pak aseptic filling and packaging capacity"
Split Ratio 1-for-25 reverse split
Effective Date November 20, 2026

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares is Cizzle Brands (CZZLF) offering, and at what price?

The base offering is 3,030,000 common shares at US$5.00 per share. The underwriter also has a 45-day option to purchase up to 454,500 additional common shares.

How much gross proceeds does Cizzle Brands (CZZLF) expect from the offering?

Gross proceeds are expected to be approximately US$15.15 million before underwriting discounts and commissions and other estimated offering expenses; this excludes any exercise of the option to purchase additional shares.

What was Cizzle Brands’ (CZZLF) share consolidation ratio?

The company’s one post-consolidation common share for every 25 pre-consolidation common shares consolidation took effect November 20, 2026. The company stated that the consolidation remains subject to Cboe Canada policies.

When will Cizzle Brands’ (CZZLF) warrants expire under the proposed extension?

The company intends to extend the expiry of 36,419,635 warrants to November 28, 2027, from November 28, 2026. The count is on a pre-consolidation basis; disinterested shareholders approved the extension, which remains subject to Cboe Canada acceptance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number:
333-298427

 

CIZZLE BRANDS CORPORATION

(Translation of registrant’s name into English)

 

35 McCleary Court, Unit 21, Concord, Ontario L4K 3Y9, Canada

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ¨  Form 40-F x

 

 

 

 

 

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

 

On November 20, 2026, Cizzle Brands Corporation (the “Registrant”) filed with the Canadian Securities Regulatory Authorities on the System for Electronic Document Analysis and Retrieval + a press release, a copy of which is attached hereto as Exhibit 99.1. Exhibits 99.1 and 99.2 are hereby incorporated by reference into the Registrant’s Registration Statement on Form F-10, as amended and supplemented (File No. 333-298427). The inclusion of any website address herein, including in any exhibit attached hereto, is intended to be an inactive textual reference only and not an active hyperlink. The information contained in, or that can be accessed through, each such website is not part of this Form 6-K or incorporated herein.

 

See “Exhibits” below.

 

Exhibits

 

Exhibit
Number
  Description
99.1   Press Release, dated November 20, 2026
99.2*   Underwriting Agreement, dated November 19, 2026

 

* Certain confidential information has been redacted pursuant to Item 601(a)(6) of Regulation S-K. The Company will furnish supplementally a copy of any redacted information to the Securities and Exchange Commission upon request. 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  CIZZLE BRANDS CORPORATION
     
  By: /s/ John Celenza
    Name: John Celenza
    Title: Chief Executive Officer
       
Date: November 20, 2026    

 

 

 

Exhibit 99.1

 

 

Cizzle Brands Corporation Announces Pricing of US$15,150,000 Public Offering and Nasdaq Listing

 

Common Shares to Trade on the Nasdaq Capital Market Under the Symbol “CZZL”

 

TORONTO, ONTARIO, CANADA – November 20, 2026 – Cizzle Brands Corporation (Cboe Canada: CZZL; OTCQB: CZZLF; Frankfurt: 8YF) (“Cizzle Brands” or the “Company”), the sports nutrition company that is elevating the game in health and wellness, today announced the pricing of its underwritten public offering (the “Offering”) in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company is offering 3,030,000 common shares at a public offering price of US$5.00 per share. The Company has also granted the Underwriter (as defined below) a 45-day option to purchase up to an additional 454,500 common shares, representing 15% of the common shares sold in the Offering. The common shares are expected to begin trading on the Nasdaq Capital Market on November 20, 2026 under the symbol “CZZL.”

 

The gross proceeds from the Offering, before deducting underwriting discounts and commissions and other estimated Offering expenses payable by the Company, are expected to be approximately US$15.15 million, excluding any exercise of the Underwriter’s option to purchase additional shares. The Offering is expected to close on or about November 23, 2026, subject to the satisfaction of customary closing conditions.

 

The Company intends to use the net proceeds of the Offering for repayment of a portion of the indebtedness incurred to finance its acquisition of Flow Water Inc.’s beverage co-manufacturing business; capital expenditures to expand production capacity at The CWENCH Hydration Factory in Aurora, Ontario, including additional Tetra Pak aseptic filling and packaging capacity and related plant and equipment; and general corporate purposes, including ongoing operations, working capital and growth initiatives. However, the Company’s management will have broad discretion with respect to the actual use of the net proceeds from the Offering.

 

Joseph Gunnar & Co., LLC (the “Underwriter”) is acting as sole book-running manager for the Offering. Research Capital Corporation is acting as an agent for the sale of common shares in the Offering in Canada.

 

A registration statement on Form F-10 (File No. 333-298427) related to the Offering of the common shares described above was filed with the United States Securities and Exchange Commission (“SEC”) and became effective on September 29, 2026 pursuant to Rule 467(b) under the U.S. Securities Act of 1933, as amended. A copy of the registration statement can be accessed by visiting the SEC website at www.sec.gov. The common shares are being offered and sold in the United States only by means of a prospectus supplement and the accompanying short form base shelf prospectus dated October 7, 2025, forming part of the registration statement. A final prospectus supplement relating to this Offering will be filed with the SEC. When available, a copy of the final prospectus supplement and accompanying base shelf prospectus may be obtained from Joseph Gunnar & Co., LLC, Prospectus Department, 40 Wall Street, 30th Floor, New York, NY 10005, telephone 212-440-9600, email: prospectus@jgunnar.com Investors may also obtain these documents at no cost by visiting the SEC’s website at www.sec.gov and under the Company’s profile on SEDAR+ at www.sedarplus.ca.

 

 

 

 

 

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering.

 

As previously disclosed, a portion of the Offering is being raised in Canada in reliance on the “listed issuer financing” exemption from the prospectus requirements available under Part 5A.2 of National Instrument 45-106 - Prospectus Exemptions, as modified by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the “Listed Issuer Financing Exemption”). An amended and restated offering document containing final pricing for the Offering (the “Offering Document”) can be accessed in English and French under the Company’s profile on SEDAR+ at www.sedarplus.ca and on the Company’s website at www.cizzlebrands.com. Prospective investors in Canada should read the Offering Document before making an investment decision concerning the common shares. Any distribution of common shares outside of Canada will be made pursuant to applicable foreign securities laws and the public offering exemption available under BC Instrument 72-503 – Distribution of Securities outside British Columbia.

 

The Company also confirms that the consolidation of its outstanding common shares on the basis of one (1) post-consolidation common share for every twenty-five (25) pre-consolidation common shares (the “Consolidation”) has taken effect as of November 20, 2026. Trading of the post-Consolidation common shares on Nasdaq and Cboe Canada is expected to commence on November 20, 2026 under the existing symbol “CZZL.” The Company’s common shares will trade under a new CUSIP number (17888V201) and ISIN (CA17888V2012). The exercise price and the number of common shares issuable under the Company’s outstanding warrants and options will be proportionately adjusted to reflect the Consolidation. Fractional shares created as a result of the Consolidation will be rounded down to the nearest whole share.

 

Following the Consolidation and assuming no additional issuances, the Company expects to have approximately 9,217,365 common shares issued and outstanding, prior to rounding for fractional shares and prior to giving effect to the Offering.

 

In connection with the Consolidation, the Company will not require a letter of transmittal from holders of common shares whose shares are held in book-entry or DRS form. All such shareholders will automatically receive the post-Consolidation Shares to which they are entitled, and Odyssey Trust Company, as transfer agent, will distribute the applicable DRS statements. Odyssey Trust Company has confirmed that all common shares of the Company held by registered shareholders as of the effective date on November 20, 2026 will be processed. The Consolidation remains subject to the policies of Cboe Canada.

 

The Company also announces that it intends to extend the expiry date of 36,419,635 outstanding common share purchase warrants (on a pre-Consolidation basis) that are currently scheduled to expire at 5:00 p.m. (Toronto time) on November 28, 2026 (the “Warrants”) by 12 months, to November 28, 2027 (the “Warrant Extension”). The Warrants were originally scheduled to expire on August 28, 2026, and their expiry date was previously extended to November 28, 2026. All other terms of the Warrants, including the exercise price of $0.40 per share (on a pre-Consolidation basis, subject to adjustment in accordance with their terms, including for the Consolidation) and the Company’s right to accelerate the expiry date, will remain unchanged. The Warrant Extension has been approved by written resolution of disinterested shareholders in accordance with the policies of Cboe Canada and remains subject to acceptance by Cboe Canada.

 

 

 

 

 

About Cizzle Brands Corporation

 

Cizzle Brands Corporation is a vertically integrated sports nutrition company that is elevating the game in health and wellness. Through extensive collaboration and testing with leading athletes and trainers across several sports, Cizzle Brands has launched three game-changing brands: (i) CWENCH Hydration™, a better-for-you sports drink that is now carried in over 6,900 locations in Canada, the United States, and Europe; (ii) Spoken™ Nutrition, a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification; and (iii) HappiEats™, upgrading everyday eats with high-performance foods such as Sport Pasta™ and SnakStars™ Sport Bites. It also owns and operates The CWENCH Hydration Factory, a manufacturing facility that produces CWENCH Hydration and other leading beverage brands in Tetra Pak packaging. All Cizzle Brands products are designed to help people of all ages achieve their best in competitive sports and in living a healthy, vibrant, active lifestyle.

 

For more information about Cizzle Brands, please visit: https://www.cizzlebrands.com

For more information about CWENCH Hydration™, please visit: https://www.cwenchhydration.com

For more information about Spoken™ Nutrition, please visit: https://www.spokennutrition.com

For more information about HappiEats™, please visit: https://www.myhappieats.com

 

On behalf of the Board of Directors of the Company,

 

CIZZLE BRANDS CORPORATION

 

“John Celenza”

John Celenza, Founder, Chairman, and Chief Executive Officer

 

For further information, please contact:

 

Setti Coscarella

Head of Corporate Development

investors@cizzlebrands.com

1-844-588-2088

 

 

 

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

 

This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian and United States securities laws (collectively, “forward-looking information”), which may include, but is not limited to, information with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, such as, but not limited to: the completion, timing, size and terms of the Offering; the commencement of trading of the Company’s common shares on the Nasdaq Capital Market and the Company’s ability to meet applicable Nasdaq listing requirements; the intended use of the net proceeds of the Offering, including the repayment of indebtedness and the expansion of production capacity at The CWENCH Hydration Factory; the completion of the Canadian portion of the Offering pursuant to the Listed Issuer Financing Exemption; the filing of the final prospectus supplement; the completion, timing and effects of the Consolidation; the receipt of required regulatory and exchange approvals, including approvals of Cboe Canada and the Nasdaq Capital Market; and the satisfaction of customary closing conditions. Such forward-looking information is often, but not always, identified by the use of words and phrases such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information, including assumptions regarding capital markets conditions and investor demand; the ability of the Company, the Underwriter and other parties to satisfy customary closing conditions; the Company’s ability to meet applicable Nasdaq listing requirements; the timely receipt of required regulatory and exchange approvals; and the absence of material adverse changes in the Company’s business, financial condition, operations or prospects. Those assumptions and factors are based on information currently available to the Company.

 

Forward-looking information involves known and unknown risks, uncertainties and other risk factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks include market volatility and adverse capital markets conditions; the risk that the Offering, including the Canadian portion of the Offering, or the Consolidation is not completed on the anticipated terms or timeline, or at all; the risk that the Company does not satisfy, or does not continue to satisfy, applicable Nasdaq listing requirements; delays in obtaining, or the failure to obtain, required regulatory or exchange approvals; management’s discretion over the use of the net proceeds of the Offering; risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks (including manufacturing facility utilization rates, dependency on third-party co-manufacturing volume commitments, and production line efficiencies), reliance on third-party logistics (3PL) providers and outsourced supply chain networks, dependency on single-source or third-party suppliers for raw materials and packaging inputs (including outsourced proprietary flavour formulations), regulatory risks, financing, capitalization and liquidity risks; and the risks described under “Risk Factors” in the prospectus supplement and the Company’s registration statement on Form F-10, as amended, the prospectus supplement relating to the Offering and the Company’s continuous disclosure filings available under its profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation, except as otherwise required by law, to update this forward-looking information if management’s beliefs, estimates or opinions, or other factors change.

 

Neither Cboe Canada nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

 

 

 

Exhibit 99.2

 

UNDERWRITING AGREEMENT

 

New York, New York

November 19, 2026

 

Joseph Gunnar & Co., LLC

as Representative of the several Underwriters named in Schedule 1 hereto

1000 RXR Plaza

Uniondale, New York 11556

 

Ladies and Gentlemen:

 

The undersigned, CIZZLE BRANDS CORPORATION, a corporation incorporated under the laws of the Province of British Columbia, Canada (together with its subsidiaries, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries of CIZZLE BRANDS CORPORATION, the “Company”), proposes to issue and sell an aggregate of 3,030,000 common shares of the Company, with no par value per share (the “Common Shares”), to Joseph Gunnar & Co., LLC (“Joseph Gunnar”) and each of the other underwriters, if any, named in Schedule 1 hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 6 hereof), for which Joseph Gunnar is acting as representative (in such capacity, the “Representative” and if there are no Underwriters other than Joseph Gunnar, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriters) in the respective amounts set forth opposite their names on Schedule 1 hereto, pursuant to the underwritten offering contemplated by this Agreement (the “Offering”).

 

The 3,030,000 Common Shares to be sold by the Company to the Underwriters pursuant to the Offering are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to 454,500 additional Common Shares as provided in Section 1.4.1 (the “Over-Allotment Option”). Such 454,500 additional Common Shares are hereinafter referred to as the “Option Shares.” The Firm Shares and, if and to the extent the Over-Allotment Option is exercised, the Option Shares are collectively called the “Offered Shares.” The share and per-share information in this Agreement gives effect to the consolidation of the Common Shares on the basis of one post-consolidation Common Share for every twenty-five pre-consolidation Common Shares effective November 20, 2026 (the “Consolidation”).

 

The Company understands that the Underwriters propose to complete: (i) a public offering of the Offered Shares in the United States, either directly or through their respective U.S. broker-dealer affiliates, upon the terms set forth in the Time of Sale Prospectus and the U.S. Final Prospectus; and (ii) a private placement of the Offered Shares to Substituted Purchasers in each of the provinces and territories of Canada (other than Quebec) (collectively, the “Canadian Selling Jurisdictions”) pursuant to the exemption from the prospectus requirement set out in Part 5A of National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”), as modified by Coordinated Blanket Order 45-935 – Exemption from Certain Conditions of the Listed Issuer Financing Exemption (collectively, the “LIFE Exemption”), as further described in the LIFE Offering Documents, through their respective Canadian broker-dealer affiliates or Canadian Selling Firms, upon the terms set forth in the LIFE Offering Documents, all as soon as the Underwriters deem advisable after this Agreement has been executed and delivered.

 

The Company has prepared and filed with the U.S. Securities and Exchange Commission (the “Commission”), pursuant to the Canada/United States Multi-Jurisdictional Disclosure System adopted by the applicable securities commission or securities regulatory authority in each of the Qualifying Jurisdictions (as defined below) (the “Canadian Securities Regulators”) and the Commission, a registration statement on Form F-10 (File No. 333-298427) for the registration of the offering of the Offered Shares under the United States Securities Act of 1933, as amended (the “Securities Act”), and the rules and regulations promulgated thereunder (the “Securities Act Regulations”), including the Canadian Base Prospectus (as defined below) and the Canadian Preliminary Prospectus Supplement (as defined below), in each case in the English language, with such deletions therefrom and additions or changes thereto as are permitted or required by Form F-10 and the applicable rules and regulations of the Commission. Such registration statement, as amended, at any given time, including the financial statements, exhibits and schedules thereto, the documents incorporated or deemed to be incorporated by reference therein and any information deemed to be a part thereof at the time of effectiveness pursuant to Item 4 of Form F-10 and the Securities Act, is called the “Registration Statement.”

 

 

 

 

The preliminary prospectus included in the Registration Statement at the time it became effective under the Securities Act describing the Offered Shares and the offering thereof in the United States of America, its territories and possessions, any state of the United States and the District of Columbia (the “United States”) is called the “U.S. Preliminary Prospectus,” and the U.S. Preliminary Prospectus and any other prospectus in preliminary form that describes the Offered Shares and the offering thereof and is used prior to the filing of the U.S. Final Prospectus (as defined below) in the United States is called a “U.S. preliminary prospectus.” The Company has also prepared and filed with the Commission an Appointment of Agent for Service of Process and Undertaking on Form F-X (the “Form F-X”).

 

In addition, the Company has prepared and filed:

 

(a)with the Canadian Securities Regulators in each of the provinces and territories of Canada (the “Qualifying Jurisdictions”), a preliminary short form base shelf prospectus dated September 30, 2025 (in the English language, together with all documents and information incorporated therein by reference, the “Canadian Preliminary Base Prospectus”) and a short form base shelf prospectus dated October 7, 2025, relating to the distribution of up to C$150,000,000 aggregate initial offering amount of Common Shares, preferred shares, warrants, debt securities, subscription receipts and/or units of the Company (such short form base shelf prospectus in the English language, together with all documents and information incorporated therein by reference, the “Canadian Base Prospectus”) pursuant to NI 44-101 (defined below) and NI 44-102 (defined below) (the “Shelf Procedures”); and

 

(b)with the Canadian Securities Regulators in the Qualifying Jurisdictions, a preliminary prospectus supplement dated October 26, 2026 to the Canadian Base Prospectus relating to the distribution of the Offered Shares (in the English language, together with all documents and information incorporated therein by reference, the “Canadian Preliminary Prospectus Supplement”).

 

The Canadian Preliminary Prospectus Supplement, together with the Canadian Base Prospectus, in the English language and together with all documents and information incorporated therein by reference, is hereinafter referred to as the “Canadian Preliminary Prospectus.” “Preliminary Offering Documents” means the Canadian Preliminary Prospectus and the U.S. Preliminary Prospectus, including, for greater certainty, the documents incorporated therein by reference.

 

The Company is prepared to file with the Commission, pursuant to General Instruction II.L of Form F-10, the Canadian Prospectus Supplement (as defined below), which includes pricing and other information omitted from the U.S. Preliminary Prospectus, in the English language, with such deletions therefrom and additions or changes thereto as are permitted or required by Form F-10 and the applicable rules and regulations of the Commission (the “U.S. Prospectus Supplement”). The U.S. Prospectus Supplement, together with the Canadian Base Prospectus included in the Registration Statement relating to the offer and sale of the Offered Shares in the United States, including the documents incorporated by reference therein, is herein called the “U.S. Final Prospectus.”

 

In addition, the Company is prepared to file a final prospectus supplement (the “Canadian Prospectus Supplement”) to the Canadian Base Prospectus, which includes pricing and other information omitted from the Canadian Preliminary Prospectus, in the English language, and all necessary related documents in order to qualify the Offered Shares for distribution in each of the Qualifying Jurisdictions on or before 12:00p.m. (Eastern time) on November 20, 2026, or such later date and time as may be mutually agreed upon in writing by the Company and the Representative (the “Qualification Deadline”). The Canadian Prospectus Supplement, together with the Canadian Base Prospectus, including all documents incorporated therein by reference, but excluding any prospectus supplement other than the Canadian Prospectus Supplement, is hereinafter referred to as the “Canadian Final Prospectus.” “Final Offering Documents” means the Canadian Final Prospectus and the U.S. Final Prospectus, including, for greater certainty, the documents incorporated therein by reference.

 

“Applicable Time” means 4:45p.m. Eastern time on November 20, 2026.

 

2

 

 

“Board” means the board of directors of the Company.

 

“Bona Fide Electronic Road Show” means a “bona fide electronic road show” as defined in Rule 433 of the Securities Act Regulations.

 

“Business Day” means any day, other than a Saturday, Sunday or statutory holiday, on which commercial banks are open for business in New York, New York and Toronto, Ontario.

 

“Canadian Public Disclosure Documents” means all information filed by or on behalf of the Company during the period commencing on December 1, 2024 and ending on the date hereof with the Canadian Securities Regulators in the Qualifying Jurisdictions and available for public viewing on SEDAR+ (as defined below).

 

“Canadian Securities Laws” means, collectively, all applicable securities laws in Canada and the respective rules and regulations made thereunder, together with applicable multilateral or national instruments, orders, rulings, policies, rules and other regulatory instruments issued or adopted and published by the Canadian Securities Regulators.

 

“CDS” means CDS Clearing and Depository Services Inc.

 

“distribution,” as used in this Agreement for purposes of Canadian Securities Laws matters, has the meaning given to it in the Securities Act (British Columbia).

 

“DTC” means The Depository Trust Company.

 

“Engagement Letter” means the Financing and Advisory for Listing on a National U.S. Securities Exchange Engagement Agreement dated May 19, 2026, between the Company and Joseph Gunnar, as amended by the Amending Agreement to Engagement Letter dated October 5, 2026 and the Second Amending Agreement to Engagement Letter dated November 19, 2026.

 

“Exchanges” means Nasdaq, Cboe and each other securities exchange or quotation system on which the Common Shares are then listed or quoted, and “Exchange” means any one of them, as the context requires.

 

“FINRA” means the Financial Industry Regulatory Authority, Inc.

 

“Free Writing Prospectus” means a “free writing prospectus” as defined in Rule 405 of the Securities Act Regulations.

 

“LIFE News Release” means the news release of the Company dated November 20, 2026, announcing the sale of Offered Shares pursuant to the LIFE Exemption and containing the disclosure prescribed by NI 45-106, together with any amendment or supplement thereto.

 

“LIFE Offering Document” means the listed issuer financing document of the Company dated October 23, 2026, as amended and restated on November 20, 2026, prepared by the Company in accordance with Form 45-106F19 – Listed Issuer Financing Document and Coordinated Blanket Order 45-935, as filed under the Company’s profile on SEDAR+ and posted on the Company’s website.

 

“LIFE Offering Document Amendment” means any amendment or supplement to the LIFE Offering Document, the LIFE News Release or any other LIFE Offering Documents.

 

“LIFE Offering Documents” means, collectively, the LIFE Offering Document, the LIFE News Release, the LIFE Questionnaires and any amendment or supplement to any of the foregoing, including, in each case, the documents incorporated or deemed to be incorporated therein by reference, if any.

 

“LIFE Questionnaires” means the subscriber questionnaires in respect of subscriptions for Offered Shares, in the forms agreed upon by the Underwriters and the Company, completed by each of the Substituted Purchasers providing certain information with respect to such Substituted Purchasers and shall include, for greater certainty, all schedules thereto.

 

3

 

 

“Listing” means the listing of the Common Shares on a national securities exchange in the United States, whether completed concurrently with or separately from an Offering, including by way of a direct listing application and the filing of a registration statement on Form 40-F without a concurrent financing.

 

“Material Adverse Effect” means a material adverse effect on the results of operations, assets, business, properties or condition (financial or otherwise) of the Company and its Subsidiaries on a consolidated basis.

 

“Misrepresentation” has the meaning ascribed to that term under applicable Canadian Securities Laws, and “misrepresentation” shall have the corresponding meaning.

 

“NI 44-101” means National Instrument 44-101 – Short Form Prospectus Distributions adopted by the Canadian Securities Regulators.

 

“NI 44-102” means National Instrument 44-102 – Shelf Distributions adopted by the Canadian Securities Regulators.

 

“NI 45-106” means National Instrument 45-106 – Prospectus Exemptions adopted by the Canadian Securities Regulators.

 

“NP 11-202” means National Policy 11-202 – Process for Prospectus Reviews in Multiple Jurisdictions adopted by the Canadian Securities Regulators.

 

“Offering Documents” means, collectively, the Prospectus Offering Documents and the LIFE Offering Documents.

 

“Person” means an individual, corporation, partnership, limited partnership, limited liability company, joint venture, association, trust, unincorporated organization, governmental authority or other entity.

 

“Prospectus Offering Document Amendment” means any amendment or supplement to any Prospectus Offering Document pursuant to this Agreement, including, in respect of the Canadian Final Prospectus, any amendment to the Canadian Final Prospectus, any amendment to a document incorporated or deemed incorporated therein by reference and any amendment or supplemental prospectus that may be filed by or on behalf of the Company under applicable Canadian Securities Laws relating to the offering and sale of the Offered Shares (a “Canadian Prospectus Amendment”).

 

“Prospectus Offering Documents” means the Registration Statement, the Preliminary Offering Documents, the Time of Sale Prospectus, the Final Offering Documents and any Prospectus Offering Document Amendment, including, for greater certainty, the documents incorporated or deemed to be incorporated therein by reference.

 

“Road Show” means a “road show” as defined in Rule 433 of the Securities Act Regulations relating to the Offering that is a “written communication” as defined in Rule 405 of the Securities Act Regulations.

 

“Shelf Information” means, collectively, the information included in the Canadian Prospectus Supplement that is permitted under the Shelf Procedures to be omitted from the Canadian Base Prospectus for which receipts or other evidences of acceptance have been obtained but that is deemed under the Shelf Procedures to be incorporated by reference into the Canadian Base Prospectus as of the date of and by virtue of the Canadian Prospectus Supplement.

 

“Time of Sale Prospectus” means the U.S. Preliminary Prospectus and the information included on Schedule 2 hereto, all considered together.

 

“Trading Day” means a day on which the Nasdaq is open for trading.

 

4

 

 

“Underwriters' Counsel” means counsel to the Representative acting in connection with the Offering.

 

“United States Securities Laws” means United States federal and state securities laws.

 

As used herein, the terms “Registration Statement,” “Preliminary Offering Documents,” “Time of Sale Prospectus” and “Final Offering Documents” shall include the documents incorporated or deemed to be incorporated by reference therein, including, without limitation, any marketing material incorporated or deemed incorporated therein by reference (the “Incorporated Documents”), including, unless the context requires otherwise, the documents, if any, filed as exhibits to such Incorporated Documents. References to the “LIFE Offering Documents” or any “LIFE Offering Document Amendment” include the documents incorporated or deemed to be incorporated therein by reference, if any.

 

All references in this Agreement to the Registration Statement, any U.S. preliminary prospectus, including the U.S. Preliminary Prospectus, the U.S. Final Prospectus or any amendments or supplements to any of the foregoing shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (“EDGAR”).

 

All references in this Agreement to the Canadian Preliminary Base Prospectus, the Canadian Base Prospectus, the Canadian Preliminary Prospectus, the Canadian Final Prospectus, the LIFE Offering Document, the LIFE News Release or any amendments or supplements to any of the foregoing shall include any copy thereof filed with the Canadian Securities Regulators through the System for Electronic Data Analysis and Retrieval Plus (“SEDAR+”).

 

Each Underwriter shall offer the Offered Shares for sale pursuant to the Prospectus Offering Documents in the United States and in such other jurisdictions as may be agreed upon in writing by the Company and the Representative, directly and through duly registered investment dealers or brokers and in compliance with applicable Canadian Securities Laws and United States Securities Laws.

 

Each Underwriter agrees that it will not, directly or indirectly, distribute any Prospectus Offering Document or publish any prospectus, circular, advertisement or other offering material relating to the Offering in any jurisdiction other than the United States and such other jurisdictions as may be agreed upon in writing by the Company and the Representative and in which the Offered Shares may lawfully be offered and sold.

 

The Company agrees that each Underwriter, in its capacity as an Underwriter, may, at its sole expense, appoint other appropriately registered investment dealers or brokers to assist in the offer and sale of the Offered Shares. Each dealer or broker with which an Underwriter has a contractual relationship in respect of the offer and sale of any Offered Shares is referred to herein as a “Selling Firm.”

 

Each Underwriter shall, and shall require each of its Selling Firms to, comply with applicable Canadian Securities Laws and United States Securities Laws in connection with the offer and sale of the applicable Offered Shares and shall offer and sell the Offered Shares only upon the terms and conditions, including the applicable public offering price, set forth in the Offering Documents and this Agreement.

 

No Underwriter shall, and each Underwriter shall require each of its Selling Firms not to, directly or indirectly offer, sell or deliver any Offered Shares or distribute any Offering Document in any jurisdiction except in a manner that will not require the Company to comply with any registration, prospectus, continuous disclosure, filing or other similar requirement under the securities laws of any jurisdiction, other than the requirements expressly contemplated by the Prospectus Offering Documents, the LIFE Offering Documents and this Agreement.

 

Each Underwriter shall promptly notify the Company when, in its opinion, its distribution of the Offered Shares has ceased and shall provide to the Company, as soon as practicable thereafter, a breakdown of the number of Offered Shares distributed by it and its Selling Firms in each applicable jurisdiction. The Representative may deliver a consolidated notice and distribution breakdown to the Company on behalf of the Underwriters.

 

5

 

 

The Company, each Underwriter in its capacity as an underwriter of the Offered Shares hereby agree as follows.

 

1.Purchase and Sale of Offered Shares

 

1.1On the basis of the representations, warranties and agreements of the Company herein contained and subject to the terms and conditions of this Underwriting Agreement (this “Agreement”), the Company agrees to issue and sell, and the Underwriters agree to purchase from the Company, the Firm Shares in the numbers set forth opposite the respective names of the Underwriters on Schedule 1 attached hereto and made a part hereof at a purchase price of US$4.675 per Firm Share (93.5% of the per Firm Share public offering price). The Firm Shares are to be offered initially to the public at the offering price set forth in the Time of Sale Prospectus and the Final Offering Documents.

 

1.2Notwithstanding the foregoing, the Company understands that, although the agreement to purchase the Offered Shares is made hereunder by the Underwriters to the Company as purchasers, the Underwriters shall have the right to arrange for the Offered Shares to be purchased by substituted purchasers in the Canadian Selling Jurisdictions (the “Substituted Purchasers”) in compliance with Canadian Securities Laws pursuant to the LIFE Exemption. For each Substituted Purchaser that purchases the Offered Shares the obligations of the Underwriters to do so will be reduced by the number of Offered Shares purchased by the Substituted Purchasers directly from the Company. The aggregate number of Offered Shares sold to Substituted Purchasers in reliance on the LIFE Exemption will not exceed the maximum number permitted under Part 5A of NI 45-106 and Coordinated Blanket Order 45-935, including the applicable aggregate offering-size and dilution limits, as notified by the Company to the Underwriters prior to the Applicable Time.

 

1.3Firm Shares Payment and Delivery

 

1.3.1Timing of Delivery and Payment. Delivery and payment for the Firm Shares shall be made at 10:00a.m., Eastern time, on November 23, 2026, or at such earlier time as shall be agreed upon in writing by the Company and the Representative, at the offices of Underwriters' Counsel, or at such other place (or remotely by facsimile or other electronic transmission) as shall be agreed upon in writing by the Company and the Representative. The hour and date of delivery and payment for the Firm Shares is called the “Closing Date”. The completion on the Closing Date of the purchase and sale of the Firm Shares is referred to herein as the “Closing”.

 

1.3.2Payment. Payment for the Firm Shares shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of the Company upon delivery of certificates (in form and substance satisfactory to the Underwriters) representing the Firm Shares, or through the facilities of DTC or CDS, as applicable, for the respective accounts of the Underwriters. The Firm Shares shall be registered in such name or names and in such authorized denominations as each Underwriter may separately request in writing at least two (2) full Business Days prior to the Closing Date. The Company shall not be obligated to sell or deliver the Firm Shares except upon tender of payment by the Underwriters for all of the Firm Shares in accordance with their respective purchase commitments, subject to Section 6.

 

1.4Over-Allotment Option

 

1.4.1Option Shares. For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Shares by the Underwriters, and subject to all the terms and conditions of this Agreement, the Company hereby grants to the Underwriters the Over-Allotment Option to purchase up to 454,500 Option Shares, representing fifteen percent (15%) of the Firm Shares sold in the Offering, at the same price as the Underwriters shall pay for the Firm Shares.

 

1.4.2Exercise of Option. The Over-Allotment Option granted pursuant to this Agreement may be exercised by the Underwriters as to all (at any time) or any part (from time to time) of the Option Shares within 45 days after the Closing Date. The Underwriters shall not be under any obligation to purchase any Option Shares prior to the exercise of the Over-Allotment Option. The Over-Allotment Option may be exercised by the giving of oral notice to the Company by the Representative, which notice must be confirmed in writing by overnight mail or same-day facsimile or other electronic transmission and must set forth the number of Option Shares to be purchased, the number of Option Shares to be purchased by each Underwriter in accordance with Schedule 1 or such other allocation as the Representative may determine, and the date and time for delivery of and payment for the Option Shares (the “Option Closing Date”), which shall not be later than two (2) full Business Days after the date of the notice or such other time as shall be agreed upon in writing by the Company and the Representative, at the offices of Underwriters’ Counsel, or at such other place (including remotely by facsimile or other electronic transmission) as shall be agreed upon in writing by the Company and the Representative.

 

6

 

 

1.4.3If delivery and payment for the Option Shares does not occur on the Closing Date, the Option Closing Date will be as set forth in the notice. Upon exercise of the Over-Allotment Option with respect to all or any portion of the Option Shares, subject to the terms and conditions set forth herein, (i) the Company shall become obligated to sell to the Underwriters the number of Option Shares specified in the notice and (ii) each Underwriter shall purchase the portion of the total number of Option Shares specified for it in the notice.

 

1.4.4Payment and Delivery. Payment for the Option Shares shall be made on the Option Closing Date by wire transfer in Federal (same day) funds, payable to the order of the Company upon delivery of certificates (in form and substance satisfactory to the Underwriters) representing the Option Shares, or through the facilities of DTC or CDS, as applicable, for the respective accounts of the Underwriters. The Option Shares shall be registered in such name or names and in such authorized denominations as each Underwriter may separately request in writing at least two (2) full Business Days prior to the Option Closing Date. The Company shall not be obligated to sell or deliver the Option Shares except upon tender of payment by the Underwriters for all Option Shares required to be purchased on that Option Closing Date in accordance with their respective purchase commitments, subject to Section 6.

 

1.4.5The Option Closing Date may be simultaneous with, but not earlier than, the Closing Date; and, if simultaneous with the Closing Date, the term “Closing Date” shall include delivery of the Firm Shares and Option Shares.

 

1.5LIFE Offering Documents

 

1.5.1LIFE Questionnaires. The Underwriters hereby covenant to the Company to obtain, or to cause the applicable Selling Firm to obtain, from each Substituted Purchaser a completed LIFE Questionnaire and deliver copies of such agreements to the Company on the Closing Date, together with all documentation contemplated by the LIFE Questionnaire or as may be necessary under Canadian Securities Laws in connection with the distribution of the Offered Shares under the LIFE Exemption, in form acceptable to the Company, acting reasonably.

 

1.6Compensation and Allocation

 

1.6.1Underwriting Discount. The underwriting discount applicable to the Offering shall equal six and one-half percent (6.5%) of the public offering price of each Offered Share (which shall include shares issuable to Substituted Purchasers), subject to the President’s List rate and Excluded Shares described below (the “Underwriting Discount”).

 

1.6.2Non-Accountable Expense Allowance. On each Closing Date and Option Closing Date, the Company shall pay a non-accountable expense allowance equal to one percent (1.0%) of the gross proceeds received from the sale of Offered Shares (which shall include shares issuable to Substituted Purchasers) on that date (the “Expense Allowance”).

 

7

 

 

1.6.3President’s List. The “President’s List” means the list of pre-existing investors directly sourced by the Company and not introduced by any Underwriter, designated by the Company prior to the commencement of marketing of the Offering, set forth on Schedule 3 and approved in writing by the Representative, such approval not to be unreasonably withheld, conditioned or delayed. For Offered Shares sold to a President’s List investor, the Underwriting Discount shall be 3.75% and the Agent Warrants shall cover an aggregate of 2.5% of such Offered Shares sold to persons listed on the President’s List. No Tail compensation applies to a President’s List investor.

 

1.6.4Excluded Shares. “Excluded Shares” means (i) Common Shares issued to Cliff Rucker or any affiliate or related entity in respect of amounts owing under the vendor take-back note between the Company and RI Flow Sub LLC that are rolled, converted or applied as consideration for securities in the Offering, and (ii) Common Shares issued upon conversion or rollover into the Offering of outstanding convertible notes of the Company, including notes held by or for the benefit of Ascent Partners Fund LLC, The K2 Principal Fund L.P and Fattore Glen, in each case as identified on Schedule 5. No Underwriting Discount, Expense Allowance, Agent Warrant, Tail compensation or other compensation is payable or issuable in respect of Excluded Shares. New cash invested by Cliff Rucker or an affiliate or related entity in excess of the rolled amount shall be treated as a President’s List investment.

 

1.6.5Tail. If, at any time during the twelve (12) months following the termination (other than upon a material breach by the Representative) or completion of the Offering, the Company completes any public or private financing with any investor introduced to the Company by the Representative in connection with the Offering, the Representative shall be entitled to receive the compensation otherwise payable under this Agreement with respect to such investor (the “Tail”). Notwithstanding anything to the contrary, no Tail compensation shall be payable to the Representative in respect of any financing or transaction where the Representative: (a) is offered, but declines to accept, the role contemplated by its applicable Right of First Refusal; (b) is deemed to have waived its applicable Right of First Refusal in accordance with this Agreement; or (c) otherwise elects not to act in the applicable role for such financing or transaction. For greater certainty, no Tail compensation shall be payable in respect of: (1) any President's List investor; (2) any Excluded Shares; or (3) any transaction expressly excluded from the scope of the applicable Right of First Refusal. The Company represents that it is not currently a party to any tail or similar agreement with any broker-dealer other than the Representative.

 

1.6.6Direct Payment. All Underwriting Discounts, commissions, Expense Allowances, Agent Warrants, President’s List compensation, aggregate Tail compensation and other economic benefits payable or issuable under or in connection with the Offering shall be paid or issued to the Representative. The Company shall make all payments and issuances directly to the Representative under its wire, registration and delivery instructions. Accountable expenses shall be paid or reimbursed directly to the Underwriter that incurred the applicable expense, subject to the applicable caps and supporting documentation. The Underwriters may reduce any item of their compensation or adjust the terms thereof to the extent FINRA determines or suggests that the Underwriters’ aggregate compensation exceeds FINRA rules or that its terms require adjustment; provided that the aggregate compensation payable by the Company may not be increased without the Company’s prior written consent.

 

1.6.7Authority of the Representative. The obligations and liabilities of the Underwriters are several and not joint. Any action by the Underwriters hereunder may be taken by the Representative on behalf of the Underwriters, and any such action taken by the Representative shall be binding upon the Underwriters.

 

8

 

 

1.7Agent Warrants

 

1.7.1Purchase Warrants. The Company hereby agrees to issue directly to the Representative (and/or its permitted designees) on the Closing Date or Option Closing Date, as applicable, warrants (the “Agent Warrants”) for the purchase of an aggregate number of Common Shares equal to (i) two and one-half percent (2.5%) of the Firm Shares and Option Shares issued and sold on such date to President’s List investors and (ii) five percent (5.0%) of all other Firm Shares and Option Shares issued and sold on such date, in each case excluding Excluded Shares. The number of Agent Warrants for each tranche and compensation category shall be calculated separately by multiplying the applicable number of shares actually issued and sold by the applicable warrant percentage and rounding down to the nearest whole Common Share, and any fractional Agent Warrant shall be disregarded without payment or other adjustment. The form of agreement for the Agent Warrants (each, an “Agent Warrant Agreement”), shall be exercisable, in whole or in part, during the three (3) year period commencing on the date that is six (6) months after the Closing Date, at an initial exercise price per Common Share equal to US$6.00. The Agent Warrants and the Common Shares issuable upon exercise thereof (the “Underlying Common Shares”) are hereinafter referred to together as the “Agent Securities”. The Representative understands and agrees that the Agent Warrants and the Underlying Common Shares are subject to the restrictions imposed by FINRA Rule 5110, including the applicable one hundred eighty (180)-day lock-up, and by acceptance thereof agrees that it will not sell, transfer, assign, pledge or hypothecate the Agent Warrants, or any portion thereof, or be the subject of a hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities during the applicable restricted period, except to a permitted transferee under FINRA Rule 5110 that agrees to the same restrictions. The Agent Warrant Agreement shall provide one demand registration right and unlimited piggyback registration rights, in each case, subject to the limitations, time periods and other requirements of FINRA Rule 5110. The number of Agent Warrants, exercise price, registration rights and any other term constituting underwriting compensation shall be reduced or adjusted to the extent required by FINRA; provided that no adjustment shall increase the aggregate compensation payable by the Company without the Company’s prior written consent.

 

1.7.2Delivery. Delivery of the Agent Warrants shall be made on the Closing Date or Option Closing Date, as applicable, and shall be issued directly in the name or names and in such authorized denominations as the Representative may request, in compliance with applicable United States Securities Laws, Canadian Securities Laws and the rules of FINRA.

 

2.Representations and Warranties of the Company.

 

The Company represents and warrants to each of the Underwriters in respect of the Offering as of the Closing Date and as of each Option Closing Date, if any, as applicable, as follows (unless otherwise indicated, and all references to the Company in this Section 2 shall include the Company and its Subsidiaries):

 

2.1Compliance with Registration Requirements. The Registration Statement became effective on September 29, 2026 pursuant to Rule 467(b) under the Securities Act. The Company has complied, to the Commission’s satisfaction, with all requests of the Commission for additional or supplemental information, if any. Neither the Commission nor, to the Company’s knowledge, any state regulatory authority has issued any order preventing or suspending the use of the Registration Statement, the U.S. Preliminary Prospectus or the U.S. Final Prospectus or has instituted or, to the Company’s knowledge, threatened to institute, any proceedings with respect to such an order.

 

2.2Pursuant to the Exchange Act. The Company will file with the Commission a Form 8-A providing for the registration pursuant to Section 12(b) of the Exchange Act of the Common Shares, which registration statement complies in all material respects with the Exchange Act. The registration of the Common Shares under the Exchange Act became effective on or prior to the date hereof. The Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Shares under the Exchange Act, nor has the Company received any notification that the Commission is contemplating terminating such registration.

 

2.3Stock Exchange Listing. The Company’s Common Shares are currently quoted on the OTCQB under the symbol “CZZLF” and are listed on Cboe Canada (“Cboe”) under the symbol “CZZL” and on the Frankfurt Stock Exchange under the symbol “8YF”. The Common Shares have been approved for listing on the Nasdaq Capital Market (the “Nasdaq”), and the Company has taken no action designed to, or likely to have the effect of, delisting the Common Shares from the Nasdaq or from the Cboe, nor has the Company received any notification that the Nasdaq or the Cboe is contemplating terminating either such listing or the Company is out of compliance with the listing or maintenance requirements of the Nasdaq or the Cboe. Upon listing on the Nasdaq, the Company’s Common Shares will trade under the symbol “CZZL” on the Nasdaq and will continue to trade under the symbol “CZZL” on the Cboe.

 

9

 

 

2.4Foreign Private Issuer. The Company is a “foreign private issuer” (as defined in Rule 405 under the Securities Act) and the Registration Statement properly registers the offering of the Offered Shares under the Securities Act. The Company has prepared and filed with the Commission an Appointment of Agent for Service of Process and Undertaking on Form F-X in conjunction with the filing of the Registration Statement. The Registration Statement and the Form F-X conform, and any further amendments to the Registration Statement or the Form F-X will conform, in all material respects to applicable requirements of the Securities Act.

 

2.5Disclosures in Registration Statement.

 

2.5.1Compliance with Securities Act and 10b-5 Representation.

 

(i)Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material respects with the requirements of the Securities Act and the Securities Act Regulations. The U.S. Preliminary Prospectus, and any other U.S. preliminary prospectus, and the U.S. Final Prospectus, at the time it was filed with the Commission, complied in all material respects with the requirements of the Securities Act and the Securities Act Regulations. The U.S. Preliminary Prospectus delivered to the Underwriters for use in connection with the Offering and the U.S. Final Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

 

(ii)The Registration Statement, at its effective time, including any information omitted from the Registration Statement at the time the Registration Statement became effective but that is deemed to be part of and included in the Registration Statement pursuant to General Instruction II.L. of Form F-10 under the Securities Act, did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. No post-effective amendment to the Registration Statement reflecting any facts or events arising after the effective time which represent, individually or in the aggregate, a fundamental change in the information set forth therein is required to be filed with the Commission; provided, however, that this representation and warranty shall not apply to statements made or statements omitted in reliance upon and in conformity with Underwriter Information (as defined below) furnished by the applicable Underwriter expressly for inclusion in the Registration Statement.

 

(iii)For purposes of this Agreement, “Underwriter Information” means only written information concerning an Underwriter that such Underwriter has furnished to the Company expressly for inclusion in an applicable Offering Document and has identified in writing as information supplied by that Underwriter for that purpose.

 

(iv)The Time of Sale Prospectus, as of the Applicable Time, did not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to Underwriter Information furnished by the applicable Underwriter expressly for inclusion therein.

 

(v)None of the Preliminary Offering Documents, the Final Offering Documents or any amendment or supplement thereto, as of their respective issue dates, at the time of any filing with the Commission or the Canadian Securities Regulators, as applicable, at the Closing Date or at any Option Closing Date, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to Underwriter Information furnished by the applicable Underwriter expressly for inclusion therein.

 

10

 

 

(vi)No Underwriter Information furnished by one Underwriter shall constitute Underwriter Information of the other Underwriter.

 

2.5.2Disclosure of Agreements. The agreements and documents described in each of the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents conform in all material respects to the descriptions thereof contained therein, and there are no agreements or other documents required by the Securities Act, the Securities Act Regulations and applicable Canadian Securities Laws to be described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents or to be filed with the Commission as exhibits to the Registration Statement, that have not been so described or filed. Each agreement or other instrument (however characterized or described) to which the Company is a party or by which it is or may be bound or affected and (i) that is referred to in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, or (ii) is material to the Company’s business, has been duly authorized and validly executed by the Company, is in full force and effect in all material respects and is enforceable against the Company and, to the Company’s knowledge, the other parties thereto, in accordance with its terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally, (y) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws, and (z) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. None of such agreements or documents has been assigned by the Company, and neither the Company nor, to the Company’s knowledge, any other party is in default thereunder and, to the Company’s knowledge, no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute a default thereunder. To the Company’s knowledge, performance by the Company of the material provisions of such agreements or documents will not result in a violation of any applicable law, rule, regulation, judgment, order or decree of any governmental or regulatory agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or business (each, a “Governmental Entity”).

 

2.5.3Prior Securities Transactions. Since April 1, 2026, no securities of the Company have been sold by the Company or to its knowledge by or on behalf of, or for the benefit of, any person or persons controlling, controlled by or under common control with the Company, except as disclosed in the Canadian Public Disclosure Documents, the Registration Statement, the Time of Sale Prospectus and the Preliminary Offering Documents.

 

2.5.4Regulations. The disclosures in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents concerning the effects of federal, state, local and all foreign laws, rules and regulations relating to the Offering and the Company’s business as currently contemplated are correct in all material respects, and no other such regulations are required by the Securities Act, the Securities Act Regulations and applicable Canadian Securities Laws to be disclosed in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents which are not so disclosed.

 

2.5.5No Other Distribution of Offering Materials. The Company has not, directly or indirectly, distributed and shall not distribute any offering material in connection with the Offering other than any Preliminary Offering Document, the Final Offering Documents, the LIFE Offering Documents and other materials, if any, permitted under the Securities Act and consistent with Section 3.3 and Section 3.4 below.

 

11

 

 

2.6Changes After Dates in Registration Statement.

 

2.6.1No Material Adverse Change. Since the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, except as otherwise specifically stated therein: (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect (as defined below) and no material adverse change in the financial position or results of operations of the Company, nor any change or development that, singularly or in the aggregate, would involve a material adverse change in or affecting the condition (financial or otherwise), results of operations, business or assets of the Company and its Subsidiaries on a consolidated basis (a “Material Adverse Change”); and (ii) no officer or director of the Company has resigned from any position with the Company. The Company does not have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Offered Shares contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its businesses, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least one Trading Day (as defined below) prior to the date that this representation is made.

 

2.6.2Recent Securities Transactions, etc. Subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, and except as may otherwise be indicated or contemplated herein or disclosed in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, the Company has not: (i) issued any securities (other than (x) grants under any share compensation plan and (y) shares issued upon exercise or conversion of options, warrants or convertible securities described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents) or incurred any material liability or obligation, direct or contingent, for borrowed money; or (ii) declared or paid any dividend or made any other distribution on or in respect of its capital stock.

 

2.6.3Independent Accountants. To the knowledge of the Company, MNP LLP (the “Auditor”), whose report is filed with the Commission as part of the Registration Statement, the Time of Sale Prospectus and the U.S. Final Prospectus, is an independent registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the Public Company Accounting Oversight Board. Except as may otherwise be disclosed in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, the Auditor has not, during the periods covered by the financial statements included in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, provided to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act. The Auditor is independent in accordance with the auditors’ rules of professional conduct of the Chartered Professional Accountants of British Columbia, is an independent public accountant as required under Canadian Securities Laws and there has never been a reportable event (within the meaning of National Instrument 51-102 Continuous Disclosure Obligations) between the Company and the Auditor.

 

12

 

 

2.6.4Financial Statements, etc. The financial statements, including the notes thereto, included in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, fairly present in all material respects the financial position and the results of operations of the Company at the dates and for the periods to which they apply and comply in all material respects with the applicable accounting requirements and rules and regulations of the Commission with respect thereto as in effect at the time of filing, and such financial statements have been prepared in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”), consistently applied throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit adjustments that are not expected to be material in the aggregate and do not contain all footnotes required by IFRS). Any supporting schedules included in the Registration Statement present fairly the information required to be stated therein. Except as included therein, no historical or pro forma financial statements are required to be included in the Registration Statement, the Time of Sale Prospectus or the U.S. Final Prospectus under the Securities Act or the Securities Act Regulations. The pro forma and pro forma as adjusted financial information and the related notes, if any, included in the Registration Statement, the Time of Sale Prospectus and the U.S. Final Prospectus have been properly compiled and prepared in accordance with the applicable requirements of the Securities Act and the Securities Act Regulations and present fairly the information shown therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein. All disclosures contained in the Registration Statement, the Time of Sale Prospectus or the Final Offering Documents regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission), if any, comply with Regulation G under the Exchange Act and Item 10(e) Regulation S-K under the Securities Act, if and to the extent applicable. Each of the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents discloses all material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that may have a material current or future effect on the Company’s financial condition, changes in financial condition, results of operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, (a) neither the Company nor any of its direct and indirect subsidiaries, including each entity disclosed or described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents as being a subsidiary of the Company (each, a “Subsidiary” and, collectively, the “Subsidiaries”), has incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the ordinary course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect to its capital stock, (c) there has not been any change in the capital stock of the Company, or any of its Subsidiaries, other than (i) grants under any share compensation plan, and (ii) shares issued upon exercise or conversion of options, warrants, or convertible securities described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, (d) there has not been any Material Adverse Change in the Company’s long-term or short-term debt, and (e) the Company has not altered its method of accounting.

  

2.6.5Authorized Capital; Options, etc. The Company had, at the date or dates indicated in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, the duly authorized, issued and outstanding capitalization as set forth therein. Based on the assumptions stated in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, the Company will have on the Closing Date the adjusted share capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, on the date the Registration Statement became effective, as of the Applicable Time, and on the Closing Date and any Option Closing Date, respectively, there will be no stock options, warrants or other rights to purchase or otherwise acquire any authorized but unissued Common Shares, or any security convertible or exercisable into Common Shares, or any contracts or commitments to issue or sell Common Shares or any such options, warrants, rights or convertible securities. Except as set forth in, or contemplated by, the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, no Person has any right of first refusal, pre-emptive right, right of participation or any similar right to participate in the transactions contemplated by this Agreement or any Agent Warrant Agreement. The issuance and sale of the Offered Shares and the issuance of the Agent Securities will not obligate the Company to issue Common Shares or other securities to any Person other than as expressly contemplated by this Agreement and the Agent Warrant Agreement and will not, except as set forth in, or contemplated by, the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, result in a right of any holder of securities of the Company to adjust the exercise, conversion, exchange or reset price under any of such securities. There are no shareholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s shareholders that are control persons.

 

13

 

 

2.7Valid Issuance of Securities, etc.

  

2.7.1Outstanding Securities. All issued and outstanding securities of the Company issued prior to the transactions contemplated by this Agreement have been duly authorized and validly issued and are fully paid and non-assessable and have been issued in compliance with all United States Securities Laws and all Canadian Securities Laws; the holders thereof have no rights of rescission with respect thereto, and are not subject to personal liability by reason of being such holders; and none of such securities were issued in violation of the pre-emptive rights of any holders of any security of the Company or similar contractual rights granted by the Company. The authorized Common Shares and other securities of the Company to be outstanding upon consummation of the Offering conform in all material respects to all statements relating thereto contained in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents. The offers and sales of the outstanding Common Shares were at all relevant times either registered or qualified under the Securities Act, the applicable state securities or “blue sky” laws and the applicable Canadian provincial securities laws or, based in part on the representations and warranties of the purchasers of such Common Shares, exempt or excluded from such registration or qualification requirements. The description of the Company’s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, as described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, accurately and fairly present, in all material respects, the information required to be shown with respect to such plans, arrangements, options and rights.

 

2.7.2Securities Sold Pursuant to this Agreement. The Offered Shares and the Agent Warrants have been duly authorized for issuance and sale and, when issued and paid for or, in the case of the Agent Warrants, issued in accordance with this Agreement, will be validly issued, fully paid and non-assessable, as applicable, and free and clear of all liens imposed by the Company; the holders thereof are not and will not be subject to personal liability by reason of being such holders; the Offered Shares and Agent Warrants are not and will not be subject to the pre-emptive rights of any holders of any security of the Company or similar contractual rights granted by the Company; and all corporate action required to be taken for the authorization, issuance and sale of the Offered Shares and the authorization and issuance of the Agent Securities has been duly and validly taken. The Underlying Common Shares have been duly authorized and reserved for issuance by all necessary corporate action on the part of the Company and, when paid for and issued in accordance with the applicable Agent Warrant Agreement, such Underlying Common Shares will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject to personal liability by reason of being such holders; and the Offered Shares and Agent Securities conform in all material respects to all statements with respect thereto contained in the applicable Offering Documents.

 

2.8Registration Rights of Third Parties. Except as described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable into securities of the Company have the right to require the Company to register any such securities of the Company under the Securities Act or to include any such securities in a registration statement to be filed by the Company.

 

2.9Validity and Binding Effect of Agreements. This Agreement and each Agent Warrant Agreement have been duly and validly authorized by the Company, and, when executed and delivered, will constitute, the valid and binding agreements of the Company, enforceable against the Company in accordance with their respective terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally; (ii) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws; and (iii) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.

 

14

 

 

2.10No Conflicts, etc. The execution, delivery and performance by the Company of this Agreement, each Agent Warrant Agreement, to which the Company is a party and all ancillary documents thereto, the consummation by the Company of the transactions herein and therein contemplated and the compliance by the Company with the terms hereof and thereof do not and will not, with or without the giving of notice or the lapse of time or both: (i) result in a breach of, or conflict with any of the terms and provisions of, or constitute a default under, or result in the creation, modification, termination or imposition of any lien, charge or encumbrance upon any property or assets of the Company or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company debt or otherwise) or other understanding pursuant to the terms of any agreement or instrument to which the Company is a party; (ii) result in any violation of the provisions of the Company’s Notice of Articles or Articles (as the same may be amended or restated from time to time, collectively, the “Articles”); or (iii) violate any existing applicable law, rule, regulation, judgment, order or decree of any Governmental Entity as of the date hereof; except, in each case, where the foregoing would not reasonably be expected to have a Material Adverse Effect.

 

2.11Regulatory. Except as described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents: (i) the Company has not received notice from any Governmental Entity alleging or asserting noncompliance with any Applicable Regulations (as defined in clause (ii) below) or Authorizations (as defined in clause (iii) below); (ii) the Company is and has been in compliance with federal, state, provincial or foreign statutes, laws, ordinances, rules and regulations applicable to the Company (collectively, “Applicable Regulations”), except where such non-compliance would not reasonably be expected to have a Material Adverse Effect; (iii) the Company possesses all licenses, certificates, approvals, clearances, consents, authorizations, qualifications, registrations, permits, and supplements or amendments thereto required by any such Applicable Regulations and/or to carry on its businesses as now conducted (“Authorizations”), except where the failure to possess such Authorizations would not reasonably be expected to have a Material Adverse Effect, and such Authorizations are valid and in full force and effect and the Company is not in violation of any term of any such Authorizations, except where the invalidity, ineffectiveness or violation of such Authorizations would not reasonably be expected to have a Material Adverse Effect; (iv) the Company has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Entity or third party alleging that any product, operation or activity is in violation of any Applicable Regulations or Authorizations or has any knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding, nor, has there been any material noncompliance with or violation of any Applicable Regulations by the Company that could reasonably be expected to result in the issuance of any such communication or an investigation, corrective action, or enforcement action by any Governmental Entity; and (v) the Company has not received notice that any Governmental Entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations or has any knowledge that any such Governmental Entity has threatened or is considering such action. Neither the Company nor, to the Company’s knowledge, any of its directors, officers or employees or agents has been convicted of any crime under any Applicable Regulations.

 

2.12No Defaults; Violations. No material default by the Company, or to the knowledge of the Company, by any third party exists in the due performance and observance of any term, covenant or condition of any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other material agreement or instrument evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company is a party or by which the Company may be bound or to which any of the properties or assets of the Company is subject. The Company is not (i) in violation of any term or provision of its Articles, or (ii) in violation of any franchise, license, permit, applicable law, rule, regulation, judgment or decree of any Governmental Entity, except such violations which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

15

 

 

2.13Corporate Power; Licenses; Consents.

 

2.13.1Conduct of Business. The Company has all requisite corporate power and authority, and has all necessary authorizations, approvals, orders, licenses, certificates and permits of and from all Governmental Entities that it needs as of the date hereof to conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents except for the absence of which would not reasonably be expected to have a Material Adverse Effect.

 

2.13.2Transactions Contemplated Herein. The Company has all corporate power and authority to enter into this Agreement and each Agent Warrant Agreement, and to carry out the provisions and conditions hereof and thereof, and all consents, authorizations, approvals and orders required in connection therewith have been obtained and no further action is required by the Company, the Board or its shareholders in connection herewith or therewith. No consent, authorization or order of, and no filing with, any court, government agency or other body is required for: (i) the valid issuance, sale and delivery of the Offered Shares as contemplated by the Offering Documents and this Agreement; (ii) the valid issuance of the Agent Warrants and, upon exercise thereof in accordance with the applicable Agent Warrant Agreement, the Underlying Common Shares; or (iii) the consummation of the other transactions contemplated by this Agreement and the Agent Warrant Agreement, except for such consents, authorizations, orders and filings as are required under applicable securities laws, the rules and regulations of FINRA and the rules and policies of the applicable Exchanges, including applicable post-Closing filings under Canadian Securities Laws.

 

2.13.3D&O Questionnaires. To the Company’s knowledge, all information contained in any questionnaires (the “Questionnaires”) completed by each of the Company’s directors and officers immediately prior to the Offering (the “Insiders”) as supplemented by all information concerning the Company’s directors and officers as described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, is true and correct in all material respects, and the Company has not become aware of any information which would cause the information disclosed in the Questionnaires to become materially inaccurate and incorrect.

 

2.14Litigation; Governmental Proceedings. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental proceeding pending or, to the Company’s knowledge, threatened against or involving the Company or any executive officer or director that adversely affects or challenges the legality, validity or enforceability of this Agreement, any Agent Warrant Agreement, the Offered Shares or the Agent Securities.

 

2.15Good Standing. The Company has been duly organized and is validly existing as a corporation and is in good standing under the laws of the Province of British Columbia as of the date hereof and is duly qualified to do business and is in good standing in each other jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except where the failure to qualify, singularly or in the aggregate, would not have or reasonably be expected to have a Material Adverse Effect.

 

2.16Insurance. The Company carries or is entitled to the benefits of insurance, with reputable insurers, in such amounts and covering such risks which the Company believes are reasonably adequate, including, but not limited to, directors and officers insurance coverage at least equal to C$5,000,000 and all such insurance is in full force and effect. The Company has no reason to believe that it will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not reasonably be expected to have a Material Adverse Effect.

 

2.17Transactions Affecting Disclosure to FINRA.

 

2.17.1Finder’s Fees. Except as described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, there are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder’s, consulting or origination fee by the Company or any of its officers or directors with respect to the sale of the Offered Shares hereunder or any other arrangements, agreements or understandings of the Company or, to the Company’s knowledge, any of its shareholders that may affect the Underwriters’ compensation, as determined by FINRA.

 

2.17.2Payments Within Twelve (12) Months. Except as disclosed to the Underwriters or as described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, the Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder’s fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii) to the knowledge of the Company, any person or entity that has any direct or indirect affiliation or association with any FINRA member, within the twelve (12) months prior to the date of this Agreement, other than the payment to the Underwriters as provided hereunder in connection with the Offering.

 

16

 

 

2.17.3Use of Proceeds. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or, to the knowledge of the Company, its affiliates, except as specifically authorized herein.

 

2.17.4FINRA Affiliation. There is no (i) officer or director of the Company, (ii) to the knowledge of the Company, beneficial owner of 10% or more of any class of the Company’s securities, or (iii) to the knowledge of the Company, beneficial owner of the Company’s unregistered equity securities which were acquired during the 180-day period immediately preceding the filing of the Registration Statement that is an affiliate or associated person of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA). Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, the Company (i) does not have any material lending or other relationship with any Underwriter, affiliate or lending affiliate of any Underwriter and (ii) does not intend to use any of the proceeds from the sale of the Offered Shares to repay any outstanding debt owed to any affiliate of any Underwriter.

 

2.17.5Information. All information provided by the Company in any FINRA questionnaire or other submission to Underwriters’ Counsel for use in connection with any FINRA filing or related disclosure is true, correct and complete in all material respects.

 

2.18Foreign Corrupt Practices Act. None of the Company and its Subsidiaries or, to the Company’s knowledge, any director, officer, agent, employee or affiliate of the Company and its Subsidiaries or any shareholder of the Company acting on behalf of the Company and its Subsidiaries has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions to customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official or employee of any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company (or assist it in connection with any actual or proposed transaction) that (i) could reasonably be expected to subject the Company to any damage or penalty in any civil, criminal or governmental litigation or proceeding, (ii) if not given in the past, might have had a Material Adverse Change or (iii) if not continued in the future, might adversely affect the assets, business or operations of the Company. None of the Company, its subsidiaries or, to the Company’s knowledge, any director, officer, agent, employee or affiliate thereof has violated or is in violation of the U.S. Foreign Corrupt Practices Act of 1977, as amended, the Corruption of Foreign Public Officials Act (Canada), the U.K. Bribery Act 2010 or any other applicable anti-bribery or anti-corruption law (collectively, “Anti-Corruption Laws”). The Company and its Subsidiaries have instituted, maintain and enforce policies and procedures designed to promote and ensure compliance with Anti-Corruption Laws, and the Company will not use, directly or indirectly, the proceeds of the Offering in furtherance of an offer, payment, promise to pay or authorization of payment of money or anything of value to any person in violation of any Anti-Corruption Laws.

 

2.19Compliance with OFAC. None of the Company or its Subsidiaries or, to the Company’s knowledge, any director, officer, agent, employee or affiliate of the Company or its Subsidiaries, is currently subject to or target of any U.S. sanctions administered or enforced by the U.S. government (including Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) and the U.S. Department of State), the Government of Canada (including under the Special Economic Measures Act (Canada)), the United Nations Security Council, the European Union, His Majesty’s Treasury or other relevant sanctions authority (collectively, “Sanctions”), nor is the Company or any Subsidiary located, organized or resident in a country or territory that is the subject or target of comprehensive Sanctions., The Company will not, directly or indirectly use the proceeds of the Offering hereunder, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other person or entity, (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund or facilitate any activities of or business in any country or territory that is the subject or target of comprehensive Sanctions, or (iii) in any other manner that will result in a violation of Sanctions by any person (including any person participating in the Offering, whether as underwriter, agent, advisor, investor or otherwise). For the past five years, the Company and its Subsidiaries have not knowingly engaged in, and are not now knowingly engaged in, any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or target of Sanctions.

 

17

 

 

2.20Money Laundering Laws. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the U.S. Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any applicable Governmental Entity (collectively, the “Money Laundering Laws”); and no action, suit or proceeding by or before any Governmental Entity involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

 

2.21Officer’s Certificate. Any certificate signed by any duly authorized officer of the Company and delivered to any Underwriter or Underwriters’ Counsel shall be deemed a representation and warranty by the Company to each Underwriter to which such certificate is addressed or delivered, in such Underwriter’s applicable capacity as an Underwriter, as to the matters covered thereby.

 

2.22Lock-Up Agreements. Schedule 4 hereto contains a complete and accurate list of the Company’s directors, officers and holders of 5.0% or more of the Common Shares (collectively, the “Lock-Up Parties”). The Company has caused each director and officer that is a Lock-Up Party to deliver to each Underwriter an executed Lock-Up Agreement substantially in the form attached hereto as Exhibit A (each, a “Lock-Up Agreement”) prior to the execution of this Agreement. No release or waiver of a Lock-Up Agreement shall be effective without the prior written consent of the Representative.

 

2.23Subsidiaries. Except as described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, the Company has no direct or indirect subsidiaries or variable interest entities and does not hold any equity interests in any other entity. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any lien, and all of the issued and outstanding shares of capital stock or equity interests of each Subsidiary are validly issued and fully paid, non-assessable, and free of pre-emptive and similar rights to subscribe for or purchase shares or equity interests. Except as would not reasonably be expected to have a Material Adverse Effect, all direct and indirect Subsidiaries of the Company are duly organized and in good standing under the laws of the place of organization or incorporation, and each Subsidiary is in good standing in each jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

 

2.24Related Party Transactions. There are no related party transactions involving the Company or any of its Subsidiaries or any other person required to be described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents that have not been described as required.

 

2.25Board of Directors. The Board is comprised of the persons identified in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents under the headings relating to the directors and executive officers of the Company. The qualifications of the persons serving as Board members and the overall composition of the Board comply with applicable Canadian Securities Laws and the applicable listing rules of the Nasdaq. At least one member of the Audit Committee of the Board qualifies as an “audit committee financial expert,” as such term is defined under Regulation S-K and the listing rules of the Nasdaq.

 

2.26Disclosure Controls. The Company will maintain, when applicable, disclosure controls and procedures that comply with Rule 13a-15 or 15d-15 under the Exchange Act Regulations, and such controls and procedures will, when applicable, be effective to ensure that all material information concerning the Company will be made known on a timely basis to the individuals responsible for the preparation of the Company’s Exchange Act filings and other public disclosure documents.

 

18

 

 

2.27Sarbanes-Oxley Compliance. The Company is, or at the Applicable Time and on the Closing Date will be, in material compliance with the provisions of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated thereunder (the “Sarbanes-Oxley Act”) applicable to it, and has implemented or will implement such programs and taken reasonable steps to ensure the Company’s future compliance (not later than the relevant statutory and regulatory deadlines therefor) with all of the material provisions of the Sarbanes-Oxley Act.

 

2.28Accounting Controls. The Company has established and maintains disclosure controls and procedures and internal control over financial reporting as those terms are defined in National Instrument 52-109 – Certification of Disclosure in Issuers’ Annual and Interim Filings, which (i) are designed to provide reasonable assurance that material information relating to the Company and each of its subsidiaries is made known to those within the Company and each of its Subsidiaries responsible for the preparation of the financial statements during the period in which the financial statements have been prepared and that such material information is disclosed to the public within the time periods required by applicable laws; (ii) have been evaluated by management of the Company for effectiveness as of the end of the Company’s most recent year end; and (iii) are effective in all material respects to perform the functions for which they were established. Since the end of the Company’s most recent audited fiscal year, there have been no significant deficiencies or material weakness in the Company’s internal control over financial reporting (whether or not remediated), including any material weaknesses in its internal control over financial reporting which would be required to be disclosed in a certificate issued pursuant to National Instrument 52-109 – Certification of Disclosure in Issuer’s Annual and Interim Filings, and no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company and its Subsidiaries will, when applicable, maintain systems of “internal control over financial reporting” (as defined under Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange Act and will have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with IFRS and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

 

2.29No Investment Company Status. The Company is not and, after giving effect to the Offering and the application of the proceeds thereof as described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, will not be, required to register as an “investment company,” as defined in the U.S. Investment Company Act of 1940, as amended.

 

2.30No Labor Disputes. No labor dispute with the employees of the Company or any of its Subsidiaries exists or, to the knowledge of the Company, is imminent. To the knowledge of the Company, no officer, director, key employee or consultant of the Company is in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other similar type of contract or agreement or any restrictive covenant in favor of any third party, and, to the knowledge of the Company, the continued employment of each such executive officer does not subject the Company to any liability with respect to any of the foregoing matters. The Company is in material compliance with all applicable federal, state, provincial, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours.

 

19

 

 

2.31Employee Benefit Laws. The Company is in compliance with all applicable federal, state, provincial or foreign laws relating to discrimination in the hiring, promotion or pay of employees, and all applicable federal, state, provincial or foreign wages and hours laws, except where the failure to so comply would reasonably be expected to have a Material Adverse Effect.

 

2.32Intellectual Property.

 

2.32.1Title, License or Right to Use. The Company and each of its Subsidiaries own, have valid and enforceable title to, license to, or otherwise have the right to use, all patents, patent applications, inventions, all rights, whether conveyed by operation of law or contract, to any and all inventions made by an employee working in the scope of his or her employment, trademarks, service marks, trade names, corporate names, trademark registrations, trademark applications, service mark registrations, logos, trade dress, designs, data, database rights, Internet domain names, websites, web content, copyrights, moral rights, works of authorship, licenses, proprietary information and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), and all other worldwide intellectual property and proprietary rights, including registrations and applications for registration thereof (including all rights pertaining to the foregoing anywhere in the world, including rights arising under international treaties and conventions), and all common law rights to intellectual property and associated goodwill (collectively, “Intellectual Property”) necessary for the conduct of their respective businesses as currently conducted, or which are described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents as being owned by or licensed to or used by the Company or its Subsidiaries. Where the Company and its Subsidiaries owns the Intellectual Property (the “Owned Intellectual Property”), the Owned Intellectual Property is owned by the Company or its Subsidiaries as sole and exclusive owner with good, valid and marketable title thereto, free and clear of all encumbrances. Where the Company or its Subsidiaries license the Intellectual Property (the “Licensed Intellectual Property”), to the knowledge of the Company, the Company or its Subsidiaries have valid and enforceable licenses to use any the Licensed Intellectual Property used by it in connection with, and as required for the business of the Company and its Subsidiaries. No licenses have been granted by the Company or its Subsidiaries for the Owned Intellectual Property, except as described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents.

 

2.32.2No Violation of Third -Party Intellectual Property. To the Company’s knowledge, the Company and its Subsidiaries’ conduct of their respective businesses as currently conducted does not and will not infringe, misappropriate or otherwise violate any Intellectual Property of any third party. The Owned Intellectual Property of the Company has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. To the knowledge of the Company, no Person has infringed, misappropriated or violated the Owned Intellectual Property nor does such Owned Intellectual Property infringe, misappropriate or violate the Intellectual Property of any third party. To the knowledge of the Company, there is no application pending of any other Person which would or would potentially interfere with or infringe any Owned Intellectual Property.

 

2.32.3No Pending Action. Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others: (i) challenging the Company’s rights in or to any Owned or Licensed Intellectual Property, and to the knowledge of the Company, there are no facts which would form a reasonable basis for any such action, suit, proceeding or claim; (ii) challenging the validity, enforceability or scope of any Owned Intellectual Property; or (iii) asserting that the Company or its Subsidiaries infringe, misappropriate, or otherwise violate, or would, upon the commercialization of any product or service described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents as under development, infringe, misappropriate, or otherwise violate, any Intellectual Property rights of others, and to the Company’s knowledge there are no facts which would form a reasonable basis for any such action, suit, proceeding or claim.

 

20

 

 

2.32.4Compliance; No Material Defects. To the knowledge of the Company, (i) the Company and its Subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or its Subsidiaries, except as would not reasonably be expected to have a Material Adverse Effect, and (ii) all such agreements are in full force and effect. To the Company’s knowledge, there are no material defects in any of the patents or patent applications included in the Owned Intellectual Property. With the exception of any rights intentionally abandoned based on the Company’s business judgement during the normal course of prosecution, registrations, filings and actions necessary to preserve the rights of the Company and its Subsidiaries to its Owned Intellectual Property have been made or taken in accordance with the provisions of any applicable law, rule, regulation, judgment, order or decree of any Governmental Entity and all such Owned Intellectual Property is valid and subsisting, in compliance with any applicable law, rule, regulation, judgment, order or decree of any Governmental Entity (including payment of filing, examination and maintenance fees and proofs of use) and is not subject to any unpaid maintenance fees or taxes or actions.

  

2.32.5Protection of Intellectual Property. The Company and its Subsidiaries have taken all reasonable measures, in accordance with sound industry practices, to protect, maintain and safeguard their Owned Intellectual Property and Licensed Intellectual Property, including, as appropriate, the execution of nondisclosure, confidentiality agreements and invention assignment agreements with their employees or service providers. Except as could not reasonably be expected to have a Material Adverse Effect, all employees and other developers of Owned Intellectual Property have executed written contracts with the Company or its Subsidiaries which (i) protect the confidentiality of all Owned Intellectual Property, (ii) effect the full and irrevocable assignment to the Company and its Subsidiaries of all of the Owned Intellectual Property conceived or reduced to practice by them for the Company or its Subsidiaries; and (iii) provide that employees and developers have waived all their non-assignable rights (including moral rights) in such Owned Intellectual Property in favor of the Company and its Subsidiaries.

 

2.32.6Duty of Candor and Good Faith. The Company and its Subsidiaries have complied with the duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications with respect to the Owned Intellectual Property; and in all applicable foreign offices having similar requirements, the Company and its Subsidiaries have complied with all such requirements. None of the Company Owned Intellectual Property or Licensed Intellectual Property has been obtained or is being used by the Company or its Subsidiaries in violation of any contractual obligation binding on the Company or its Subsidiaries or any of their respective officers, directors or employees or otherwise in violation of the rights of any Persons.

 

2.33Trade Secrets. The Company and its Subsidiaries have taken reasonable and customary actions to protect their rights in and prevent the unauthorized use and disclosure of trade secrets and material confidential business information (including confidential source code, ideas, research and development information, know-how, formulas, compositions, technical data, designs, drawings, specifications, research records, records of inventions, test information, financial, marketing and business data, customer and supplier lists and information, pricing and cost information, business and marketing plans and proposals) owned by the Company and its Subsidiaries, and, to the knowledge of the Company, there has been no unauthorized use or disclosure of the trade secrets or confidential business information by the Company or its Subsidiaries.

 

2.34IT Assets. Except as could not reasonably be expected to have a Material Adverse Effect, (i) the computers, software, servers, networks, data communications lines, and other information technology systems owned, licensed, leased or otherwise used by the Company or its Subsidiaries (excluding any public networks) (collectively, the “IT Assets”) operate and perform as is necessary for the operation of the business of the Company and its Subsidiaries as currently conducted as described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, and (ii) to the knowledge of the Company, such IT Assets are not infected by viruses, disabling code or other harmful code. The Company and its Subsidiaries have at all times implemented and maintained all industry standard controls, policies, procedures, and safeguards to maintain and protect the integrity, continuous operation, redundancy and security of all IT Assets.

 

21

 

 

2.35Data Privacy and Security Laws. Except as set forth in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, or would not reasonably be expected to have a Material Adverse Effect, the Company and its Subsidiaries have complied and are presently in compliance with all applicable privacy and data protection laws, judgments and orders binding on the Company or its Subsidiaries, statutes, rules and regulations of any Governmental Entity, privacy policies, and other contractual or legal obligations (collectively, the “Privacy Laws and Policies”), relating to the privacy and security of the business of the Company and its Subsidiaries including, without limitation, the information and technology systems and protection of personal data by the Company and its Subsidiaries. Except as would not reasonably be expected to have a Material Adverse Effect, the Company and its Subsidiaries have taken reasonable steps, in accordance with all Privacy Laws and Policies, to protect the personal data (as defined under applicable privacy laws) in the possession of the Company and the Subsidiaries. Except as set forth in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, to the Company’s knowledge there has been no security breach or unauthorized collection, use, disclosure, access, disablement, or modification of or relating to any such personal data and the Company has not received written notification of any security breach or unauthorized collection, use, disclosure, access, disablement, or modification of or relating to any such personal data.

 

2.36Regulatory Compliance. The Company and its Subsidiaries are, and at all times have been, in compliance in all material respects with all applicable regulations administered or enforced by the U.S. Food and Drug Administration, the Federal Trade Commission, the U.S. Department of Agriculture, Health Canada, the Canadian Food Inspection Agency and any comparable Governmental Entity, including the Federal Food, Drug, and Cosmetic Act, the Food Safety Modernization Act, the Dietary Supplement Health and Education Act, the Food and Drugs Act (Canada), the Safe Food for Canadians Act and the Natural Health Products Regulations (Canada), relating to the formulation, manufacture, packaging, labeling, nutrition and health claims, storage, import, export, distribution, marketing and advertising of the Company's products (collectively, "Food and Health Product Laws"). All products of the Company are manufactured, labeled and marketed in compliance in all material respects with Food and Health Product Laws, and the Company holds all product licences, natural product numbers, facility registrations and licences required thereunder.

 

2.37Product Recalls. Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Offering Documents, since January 1, 2025, neither the Company nor any Subsidiary (nor, to the Company's knowledge, any co-packer, supplier or distributor in respect of the Company's products) has, voluntarily or involuntarily, initiated, conducted or been requested or required by any Governmental Entity to conduct any recall, market withdrawal, stock recovery, safety alert or other notice relating to an alleged lack of safety, contamination, adulteration, misbranding or defect of any product, and, to the Company's knowledge, no facts exist that would reasonably be expected to result in any such action or in any material product liability claim.

 

2.38Manufacturing Operations. The CWENCH Hydration Factory located in Aurora, Ontario, and the manufacturing operations of Cizzle Brands Manufacturing Inc., are operated in compliance in all material respects with applicable good manufacturing practices, food safety and sanitation requirements, Environmental Laws, Food and Health Product Laws and applicable third-party certification standards (including any Safe Quality Food or similar certification required by customers). The Company holds all material licences required to operate such facility. No material equipment failure, contamination event or regulatory inspection finding has occurred that has not been fully remediated. The Company has not received any notice of any inspection observation, warning letter or untitled letter relating to such facility that, if unresolved, would constitute a Material Adverse Change.

 

2.39Flow Acquisition; Manufacturing Contracts. The acquisition of Flow Water Inc. was duly authorized and completed in accordance with its definitive agreements , and the Company has acquired good title to the shares so acquired, free of any lien other than liens disclosed in the Offering Documents. No claim for indemnity, purchase price adjustment or set-off is pending or, to the Company's knowledge, threatened under such agreements. Each manufacturing or co-packing agreement providing minimum volume commitments described in the Offering Documents is in full force and effect, and no counterparty has given notice of termination, material reduction of committed volume or dispute. The descriptions of such committed volumes and guaranteed minimum revenue in the Offering Documents are accurate in all material respects.

 

22

 

 

2.40Secured Debt. The Offering Documents accurately describe, in all material respects, the senior secured credit facility with Orion Infrastructure Capital, the vendor take-back note in favour of RI Flow LLC and the senior secured convertible notes issued to Ascent Partners LLC and other holders (collectively, the "Debt Instruments"). The Company is in compliance in all material respects with all financial and other covenants thereunder. No default or event of default has occurred or would result from the Offering, the Consolidation, the Listing or the application of proceeds. All consents of the holders of the Debt Instruments required for the Offering, and for the rollover or conversion of the Excluded Shares, have been obtained.

  

2.41Sponsorships; Partnerships. Each sponsorship, licensing, endorsement and official-partner agreement with any sports league, governing body, team or athlete that is material to the Company or described in the Offering Documents (including those with USA Hockey, USA Lacrosse, Maple Leaf Sports & Entertainment and the Company's athlete endorsers) is in full force and effect, and neither the Company nor, to the Company's knowledge, any counterparty is in material breach thereof. No such counterparty has given notice of termination or non-renewal. The Company's use of athlete names, images and likenesses and its marketing to minors comply in all material respects with applicable law and the policies of the applicable governing bodies.

 

2.42Significant Customers, Distributors and Suppliers. No customer, retailer or distributor that accounted for more than 10% of the Company's consolidated revenue in the most recent fiscal year or interim period or sole-source supplier of ingredients, Tetra Pak packaging materials or equipment, has terminated, materially reduced or adversely modified, or notified the Company of any intention to do so, its relationship with the Company.

 

2.43Product Certifications. Each product of the Company represented as NSF Certified for Sport® or as having any other third-party certification holds such certification in good standing in all material respects, and no suspension or revocation is, to the Company's knowledge, pending or threatened. All performance, health, nutrient-content and endorsement claims made in the Company's labeling and advertising (including claims of zero sugar, electrolyte content and athlete-grade quality) are truthful in all material respects, not misleading in any material respect. and adequately substantiated as required by applicable Food and Health Product Laws and U.S. Food and Drug Administration guidance.

 

2.44Taxes. Each of the Company and its Subsidiaries has filed all returns (as hereinafter defined) required to be filed with taxing authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof. Each of the Company and its Subsidiaries has paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed against the Company or such respective Subsidiary. The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including the dates of such consolidated financial statements. Except as disclosed in writing to the Underwriters, (i) no issues have been raised (and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company or its Subsidiaries, and (ii) no waivers of statutes of limitation with respect to the returns or collection of taxes have been given by or requested from the Company or its Subsidiaries. The term “taxes” means all federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatever, together with any interest and any penalties, additions to tax or additional amounts with respect thereto. The term “returns” means all returns, declarations, reports, statements and other documents required to be filed in respect to taxes.

 

2.45Employee Benefit Plan. The Company and its Subsidiaries have not established any “employee benefit plan” (as defined under the U.S. Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder).

 

2.46Ineligible Issuer. At the time of filing of the Registration Statement and any post-effective amendment thereto, at the time of effectiveness of the Registration Statement and any amendments thereto, at the earliest time thereafter that the Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations) of the Offered Shares and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined in Rule 405 of the Securities Act Regulations, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an ineligible issuer.

 

23

 

 

2.47Real Property. Except as set forth in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, the Company and its Subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real or personal property which are material to the business of the Company and its Subsidiaries taken as a whole, in each case free and clear of all liens, encumbrances, security interests, claims and defects that do not, singly or in the aggregate, adversely affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company or its Subsidiaries; and all of the leases and subleases material to the business of the Company and its Subsidiaries, considered as one enterprise, and under which the Company or any of its Subsidiaries holds properties described in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, are in full force and effect, and neither the Company nor any Subsidiary has received any notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or any Subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such Subsidiary to the continued possession of the leased or subleased premises under any such lease or sublease, except as would not reasonably be expected to have a Material Adverse Effect.

 

2.48Contracts Affecting Capital. There are no transactions, arrangements or other relationships between and/or among the Company, any of its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated entity, including, but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially affect the Company’s or any of its Subsidiaries’ liquidity or the availability of or requirements for their capital resources required to be described or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents which have not been described or incorporated by reference as required.

 

2.49Loans to Directors or Officers. There are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of business) or guarantees of indebtedness by the Company or its Subsidiaries to or for the benefit of any of the officers or directors of the Company, its Subsidiaries or any of their respective family members.

 

2.50Industry Data. The statistical and market-related data included in each of the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate or represent the Company’s good faith estimates that are made on the basis of data derived from such sources.

 

2.51Consolidation/Reverse Share Split. Except as disclosed in the Offering Documents, the Company has not completed or proposed any share consolidation, reverse share split or similar recapitalization that has not been fully reflected in the capitalization, share numbers and per-share information contained in this Agreement and the Offering Documents.

 

2.52Emerging Growth Company. From the time of filing the Registration Statement with the Commission through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).

 

2.53Testing-the-Waters Communications. The Company has not engaged and has not authorized the Underwriters to engage in any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act or Rule 163B of the Securities Act Regulations.

 

2.54Electronic Road Show. The Company has made available any Bona Fide Electronic Road Show in compliance with Rule 433(d)(8)(ii) of the Securities Act Regulations such that no filing of any “road show” (as defined in Rule 433(h) of the Securities Act Regulations) is required in connection with the Offering.

 

24

 

 

2.55Margin Securities. The Company owns no “margin securities” as that term is defined in Regulation U of the Board of Governors of the Federal Reserve System (the “Federal Reserve Board”), and none of the proceeds of Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for any other purpose which might cause the Common Shares to be considered a “purpose credit” within the meanings of Regulation T, U or X of the Federal Reserve Board.

 

2.56Environmental Laws.

 

2.56.1Compliance. The Company and its Subsidiaries are in compliance with all applicable federal, state, provincial and local laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety or the environment which are applicable to their businesses (“Environmental Laws”), except where such non-compliance would not reasonably be expected to have a Material Adverse Effect.

 

2.56.2Permits. The Company has all permits, authorizations and approvals required under any applicable Environmental Laws and is in compliance with their requirements, except where the failure to have or be in compliance with such permits, authorizations and approvals would not reasonably be expected to have a Material Adverse Effect.

 

2.56.3Hazardous Substances. There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission or other release of any kind of toxic or other wastes or other hazardous substances by, due to, or caused by the Company or any of its Subsidiaries (or, to the Company’s knowledge, any other entity for whose acts or omissions the Company or any of its Subsidiaries is or may otherwise be liable) upon any of the property now or previously owned or leased by the Company or any of its Subsidiaries, in violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law, statute, ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit, give rise to any liability, except for any violation or liability which would not reasonably be expected to have, singularly or in the aggregate with all such violations and liabilities, a Material Adverse Effect; and there has been no disposal, discharge, emission or other release of any kind by the Company or its Subsidiaries in violation of Environmental Laws onto such property or into the environment surrounding such property of any toxic or other wastes or other hazardous substances with respect to which the Company has knowledge.

 

2.56.4No Pending or Threatened Proceedings. There are no pending or, to the knowledge of the Company, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of non-compliance or violation, investigation or proceedings relating to any Environmental Laws against the Company.

 

2.56.5No Basis for Action. To the knowledge of the Company, there are no events or circumstances that would reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or Governmental Entity against or affecting the Company relating to any Environmental Laws.

 

2.57Compliance with FTC, U.S. Department of Health and Human Services. There is no complaint to or audit, proceeding, investigation (formal or informal) or claim currently pending against the Company or its Subsidiaries, or to the knowledge of the Company, any of its customers (specific to the customer’s use of the products or services of the Company) by the Federal Trade Commission, the U.S. Department of Health and Human Services and any office contained therein, or any similar authority in any jurisdiction other than the United States or any other Governmental Entity, and, to the knowledge of the Company, no such complaint, audit, proceeding, investigation or claim is threatened.

 

2.58Forward-Looking Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or the Final Offering Documents has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.

 

25

 

 

2.59Export and Import Laws. The Company and its Subsidiaries, and any director, officer or employee of the Company and its Subsidiaries, has acted at all times in compliance in all material respects with applicable Export and Import Laws (as defined below) and there are no claims, complaints, charges, investigations or proceedings pending or, to the knowledge of the Company, threatened between the Company or any of its Subsidiaries and any Governmental Entity under any Export or Import Laws. The term “Export and Import Laws” means the Arms Export Control Act, the International Traffic in Arms Regulations, the Export Administration Act of 1979, as amended, the Export Administration Regulations, and all other applicable laws and regulations of the United States government regulating the provision of services to non-U.S. parties or the export and import of articles or information from and to the United States, and all applicable similar laws and regulations of any foreign government regulating the provision of services to parties not of the foreign country or the export and import of articles and information from and to the foreign country to parties not of the foreign country.

 

2.60Integration. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause the Offering to be integrated with prior offerings by the Company for purposes of the Securities Act that would require the registration of any such securities under the Securities Act.

 

2.61Corporate Records. The corporate records of the Company and its Subsidiaries have been made available to the Underwriters and Underwriters’ Counsel, and such corporate records accurately reflect, in all material respects, all material transactions referred to therein. There are no material transactions, agreements, dispositions or other actions of the Company or its Subsidiaries that are not properly approved and accurately reflected in such corporate records.

 

2.62Stabilization. Neither the Company nor, to its knowledge, any of its officers, directors, affiliates or representatives has taken, directly or indirectly, any action designed to stabilize, maintain or manipulate the price of any security of the Company, except with the prior written consent of the Representative where such consent is required under this Agreement.

 

2.63Canadian Securities Laws.

 

2.63.1The Company is a reporting issuer in each of the provinces and territories of Canada, is not in default of any material requirement of Canadian Securities Laws and is not included on a list of defaulting reporting issuers maintained by the securities regulators of the Qualifying Jurisdictions. The Company satisfies, and from the date of the initial LIFE News Release through the Closing will satisfy, the conditions applicable to the Company’s reliance on the LIFE Exemption, including the applicable reporting issuer, exchange-listing, continuous disclosure, active operations, offering-size, dilution, sufficient-funds and permitted-use-of-proceeds requirements. The LIFE Offering Documents accurately describe the statutory rights of purchasers and the resale treatment applicable to the Offered Shares sold to Substituted Purchasers pursuant to the LIFE Exemption. All information and statements contained in the LIFE Offering Document are true and correct in all material respects. The LIFE Offering Document, together with any document filed by the Company under Canadian Securities Laws in the 12 months preceding the date of the LIFE Offering Document, contains disclosure of all material facts about the Offered Shares being distributed under the LIFE Exemption and does not contain a Misrepresentation, and the LIFE Offering Document and the LIFE News Release comply in all material respects with Canadian Securities Laws.

 

2.63.2The Company is in compliance in all material respects with its timely and continuous disclosure obligations under Canadian Securities Laws and the Company is not in default of its filings under, nor has it failed to file or publish any document required to be filed or published under, Canadian Securities Laws and, without limiting the generality of the foregoing, there has not occurred any Material Adverse Change since the respective dates as of which information is given in the Canadian Public Disclosure Documents that has not been publicly disclosed on a non-confidential basis, and the Company has not filed any confidential material change report which remains confidential as of the date hereof.

 

26

 

 

2.63.3The Canadian Public Disclosure Documents were prepared in accordance with and comply in all material respects with Canadian Securities Laws.

 

2.63.4There are no reports or information that, in accordance with the requirements of the Canadian Securities Regulators or Canadian Securities Laws, must be made publicly available in connection with the Offering that have not been made publicly available as required. There are no documents required to be filed with the Canadian Securities Regulators in connection with the Offering that have not been filed as required, other than any post-Closing filings required to be made by the Company pursuant to Canadian Securities Laws.

 

2.64Shelf Procedures Eligibility.

 

2.64.1The Company is qualified under NI 44-101 to file a prospectus in the form of a short form prospectus in the Qualifying Jurisdictions and is eligible to use the Shelf Procedures.

 

2.64.2The Company has prepared and filed with the Canadian Securities Regulators in accordance with the Shelf Procedures the Canadian Base Prospectus and has obtained receipts for the Canadian Base Prospectus from the Ontario Securities Commission for and on behalf of itself and each of the other Canadian Securities Regulators. The aggregate amount of securities distributed pursuant to the Canadian Base Prospectus does not and, upon completion of the Offering, will not exceed the maximum aggregate amount permitted thereunder.

 

3.Covenants of the Company.

 

The Company covenants and agrees as follows:

 

3.1Final Prospectus Supplement Filing. The Company will, as soon as possible following the execution of this Agreement but, in any event, (i) no later than the Qualification Deadline, file the Canadian Prospectus Supplement including the Shelf Information in a form approved by the Underwriters, acting reasonably, in accordance with the passport system procedures provided for under NP 11-202 (the “Passport System”) with the Ontario Securities Commission (in its capacity as the principal regulator under the Passport System) and with the Canadian Securities Regulators in each of the Qualifying Jurisdictions and (ii) no later than one Business Day after the filing of the Canadian Prospectus Supplement with the Canadian Securities Regulators in the Qualifying Jurisdictions, file with the Commission on EDGAR the U.S. Final Prospectus in a form approved by the Underwriters, acting reasonably, and advise the Underwriters promptly when each such filing has been made.

 

3.2LIFE Offering Documents. The Company shall issue and file the LIFE News Release and the LIFE Offering Document in the form and within the time prescribed by Part 5A of NI 45-106 and shall not amend, amend and restate, supplement, file, issue or use any LIFE Offering Documents without first furnishing a draft to the Representative and Underwriters’ Counsel, giving the Representative a reasonable opportunity to review and comment and obtaining the approval of the Representative as to the form and substance thereof, such approval not to be unreasonably withheld, conditioned or delayed.

 

3.3Compliance with United States Federal Securities Laws.

 

3.3.1The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act, the Exchange Act Regulations and applicable Canadian Securities Laws so as to permit the completion of the distribution of the Offered Shares as contemplated in this Agreement, the Registration Statement, the Time of Sale Prospectus and the U.S. Final Prospectus. Without limiting the generality of the foregoing, the Company will, during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered, whether physically or through compliance with Rule 172 or any similar rule, file on a timely basis with the Commission and the applicable Exchange all reports and documents required to be filed under the Exchange Act.

 

27

 

 

3.3.2The Company will notify the Representative and Underwriters’ Counsel promptly, and confirm the notice in writing: (i) when any post-effective amendment to the Registration Statement shall become effective or any amendment or supplement to the U.S. Preliminary Prospectus or the U.S. Final Prospectus shall have been filed; (ii) of the receipt of any comments from the Commission; (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the U.S. Preliminary Prospectus or the U.S. Final Prospectus or for additional information; (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment, any order preventing or suspending the use of the U.S. Preliminary Prospectus or the U.S. Final Prospectus, or the suspension of the qualification of the Offered Shares or any Agent Securities registered under the Securities Act for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any such purpose or of any examination pursuant to Section 8(d) or 8(e) of the Securities Act concerning the Registration Statement; and (v) if the Company becomes the subject of a proceeding under Section 8A of the Securities Act in connection with the offering of the Offered Shares or any Agent Securities registered under the Securities Act.

 

3.3.3If at any time when a prospectus relating to the Offered Shares is, or but for the exception afforded by Rule 172 would be, required by the Securities Act to be delivered in connection with sales of the Offered Shares, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to: (i) amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii) amend or supplement the Time of Sale Prospectus or the U.S. Final Prospectus in order that it will not include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein not misleading in light of the circumstances existing at the time it is delivered to a purchaser; or (iii) amend the Registration Statement or amend or supplement the Time of Sale Prospectus or the U.S. Final Prospectus in order to comply with the Securities Act or the Securities Act Regulations, the Company shall promptly: (A) give the Representative and Underwriters’ Counsel notice of such event; (B) prepare any amendment or supplement necessary to correct such statement or omission or cause the applicable document to comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representative and Underwriters’ Counsel with copies thereof; and (C) file such amendment or supplement with the Commission; provided that the Company shall not file or use any such amendment or supplement to which the Representative or Underwriters’ Counsel reasonably objects in writing.

 

3.4Compliance with Canadian Securities Laws.

 

3.4.1The Company shall comply with the Canadian Securities Laws so as to permit the completion of the distribution of the Offered Shares as contemplated in this Agreement and in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents. The Company shall comply with Part 5A of NI 45-106, any applicable exemptive relief and all Canadian Securities Laws applicable to permit the sale to Substituted Purchasers in reliance on the LIFE Exemption, including all applicable eligibility, offering-size, dilution, sufficient-funds, permitted-use-of-proceeds, selling-jurisdiction, purchaser-rights, prescribed disclosure, filing and closing requirements. If a material change, new material fact or misrepresentation arises before completion of the Offering, the Company shall immediately notify the Representative, cease distribution when required, prepare and file on SEDAR+ any required LIFE Offering Document Amendment (in form and substance satisfactory to the Representative, acting reasonably), post such LIFE Offering Document Amendment on the Company’s website, issue a prescribed news release (in form and substance satisfactory to the Representative, acting reasonably) announcing the amendment, and resume distribution only after compliance with Canadian Securities Laws.

 

28

 

 

3.4.2If, during such period after the first date of the public offering of the Offered Shares based upon the reasonable advice of counsel for the Underwriters, any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Canadian Prospectus Supplement in order to make the statements therein, in the light of the circumstances in which they were made, not misleading, or if, based upon the reasonable advice of counsel for the Underwriters, it is necessary to amend or supplement the Canadian Prospectus Supplement to comply with applicable law, the Company will forthwith prepare and file with the Canadian Securities Regulators in the Qualifying Jurisdictions, either amendments or supplements to the Canadian Prospectus Supplement so that the statements in the Canadian Prospectus Supplement as so amended or supplemented will not, in the light of the circumstances in which they were made, be misleading or so that the Canadian Prospectus Supplement, as amended or supplemented, will comply with applicable law.

 

3.4.3In the event that the Company is required by Canadian Securities Laws (as a result of a change in Canadian Securities Laws or otherwise) to prepare and file a Canadian Prospectus Amendment, the Company shall prepare and deliver promptly to the Underwriters signed and certified copies of such Canadian Prospectus Amendment in the English language. Concurrently with the delivery of any Canadian Prospectus Amendment, the Company shall deliver to the Underwriters, with respect to such Canadian Prospectus Amendment, documents similar to those referred to in Sections 3.8 and 3.9.

 

3.5Consultation with Underwriters. In addition to the matters set out above in Sections 3.3 and 3.4, the Company will, in good faith, discuss with the Underwriters any change, event or fact contemplated in those Sections which is of a nature that there may be reasonable doubt as to whether notice should be given to the Underwriters and will consult with the Underwriters with respect to the form and content of any Prospectus Offering Document Amendment, it being understood and agreed that no such Prospectus Offering Document Amendment will be filed with any Canadian Securities Regulator or the Commission, and no Prospectus Offering Document Amendment will be distributed, prior to review by the Underwriters and their counsel, and the Company shall permit the Underwriters to reasonably review and participate in the preparation of any Prospectus Offering Document Amendment and shall allow each of the Underwriters to conduct any due diligence investigations which it reasonably requires in order to fulfill its obligations as an underwriter under United States Securities Laws or Canadian Securities Laws.

 

3.6Exchange Act Registration. For a period of three years after the date of this Agreement, the Company shall use its commercially reasonable efforts to maintain the registration of the Common Shares under the Exchange Act and shall not deregister the Common Shares under the Exchange Act without the prior written consent of the Representative; provided that the foregoing requirement shall automatically terminate upon the consummation of a Fundamental Transaction. “Fundamental Transaction” means that the Company shall, directly or indirectly, in one or more related transactions: (i) sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of its properties or assets to any other person that is not an affiliate of the Company; or (ii) consummate a share purchase agreement or other business combination, including a reorganization, recapitalization, spin-off or plan of arrangement, with any other person whereby such other person acquires more than 50% of the outstanding Common Shares, not including Common Shares held by the other Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such share purchase agreement or other business combination, and such transaction is not primarily for the purpose of raising capital.

 

3.7Free Writing Prospectuses. The Company shall not make any offer relating to the Offered Shares that would constitute a Free Writing Prospectus. No LIFE Offering Documents may be used unless approved in writing by the Company and the Representative and included within the LIFE Offering Documents to the extent required by Canadian Securities Laws.

 

3.8Delivery to the Underwriters of Registration Statement. The Company has delivered or made available, or shall deliver or make available, to each Underwriter and Underwriters’ Counsel, upon request and without charge, signed copies of the Registration Statement as originally filed and each amendment thereto, including exhibits filed therewith or incorporated by reference therein, documents incorporated or deemed incorporated by reference therein and signed copies of all consents and certificates of experts. The Company will also deliver to each Underwriter, upon request and without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto, without exhibits. The copies of the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted copies filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

 

29

 

 

3.9Delivery to the Underwriters of Offering Documents. The Company has delivered or made available, or will deliver or make available, to each Underwriter, without charge, as many copies of the U.S. Preliminary Prospectus as such Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Offered Shares is, or but for the exception afforded by Rule 172 would be, required to be delivered under the Securities Act, such number of copies of the U.S. Final Prospectus, as amended or supplemented, as such Underwriter may reasonably request. The U.S. Final Prospectus and any amendments or supplements thereto furnished to the Underwriters will be identical to the copies filed electronically with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T. Neither the Company nor any of its directors or officers has distributed, and none of them will distribute, prior to the Closing Date or Option Closing Date, as applicable, any offering material in connection with the offering and sale of the Offered Shares other than the Registration Statement, the Time of Sale Prospectus, the U.S. Final Prospectus and copies of documents incorporated therein by reference, or the LIFE Offering Documents approved in accordance with this Agreement.

 

3.10Review of Financial Statements. For a period of three (3) years after the date of this Agreement, the Company, at its expense, shall cause its regularly engaged independent registered public accounting firm to review (but not audit) the Company’s interim financial statements for each of the three fiscal quarters that are not its fourth fiscal quarter immediately preceding the announcement of any quarterly financial information; provided that the foregoing requirement shall automatically terminate upon the consummation of a Fundamental Transaction.

 

3.11Listing. The Company shall use its commercially reasonable efforts to maintain the listing of the Common Shares (including the Offered Shares) on Nasdaq and unless the Common Shares are voluntarily delisted from Cboe in connection with a consolidation of trading on Nasdaq, on Cboe (or another stock exchange in the United States or Canada, respectively, including any successors to the foregoing) for at least three (3) years from the date of this Agreement; provided that the foregoing requirement shall automatically terminate upon the consummation of a Fundamental Transaction.

 

3.12Financial Public Relations Firm. The Company shall consult with the Representative regarding an appropriate budget for, and the engagement of, one or more investor relations or financial public relations firms experienced in assisting issuers in public offerings of securities and in their relationships with security holders. The Company shall retain sole discretion with respect to the budget for and selection of any such investor relations or financial public relations firm.

 

3.13Application of Net Proceeds. Subject to the limitations and qualifications contained therein, the Company shall apply the net proceeds from the Offering received by it in a manner consistent in all material respects with the application thereof described under the caption “Use of Proceeds” in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents. The Company shall apply the net proceeds from sales made pursuant to the LIFE Exemption only to the uses disclosed in the LIFE Offering Documents and permitted by Part 5A of NI 45-106 and shall maintain records sufficient to demonstrate compliance with applicable sufficient-funds and use-of-proceeds requirements. The Company shall not use LIFE proceeds for any purpose prohibited by Canadian Securities Laws.

 

3.14Rule 158. The Company shall timely file such reports pursuant to the Exchange Act as are necessary in order to make generally available to its security holders as soon as practicable an earnings statement for the purposes of, and to provide to the Underwriters the benefits contemplated by, the last paragraph of Section 11(a) of the Securities Act and Rule 158 of the Securities Act Regulations.

 

30

 

 

3.15Internal Controls. The Company shall maintain a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary in order to permit preparation of financial statements in accordance with IFRS and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

 

3.16Accountants. The Company shall annually recommend to its shareholders an independent registered public accounting firm, and the Company shall continue to retain a nationally recognized independent registered public accounting firm for a period of at least three years after the date of this Agreement. Each Underwriter acknowledges separately that the Auditor is acceptable to it as of the date of this Agreement.

 

3.17Directors’ and Officers’ Insurance. For so long as the Agent's Warrants are outstanding, the Company shall obtain and maintain directors’ and officers’ liability insurance at a level acceptable to the Representative, acting reasonably, and shall cause each Underwriter to be included as a named insured thereunder if the additional cost of doing so is not material.

 

3.18FINRA. The Company shall advise each Underwriter and Underwriters’ Counsel if it is or becomes aware that: (i) any officer or director of the Company; (ii) any beneficial owner of 10% or more of any class of the Company’s equity securities; or (iii) to the knowledge of the Company, any beneficial owner of the Company’s unregistered equity securities acquired during the 180 days immediately preceding the original filing of the Registration Statement, is or becomes an affiliate or associated person of a FINRA member participating in the Offering, as determined in accordance with FINRA’s rules and regulations. The Representative may make or coordinate the applicable FINRA filing on behalf of the Underwriters.

 

3.19Securities Laws Disclosure; Pre-Closing Publicity. At the request of the Representative, by 9:00 a.m. New York City time on the date following the date hereof, the Company shall issue a press release disclosing the material terms of the Offering. The Company shall issue the LIFE News Release and any required LIFE Offering Document Amendment news release in the form and within the time prescribed by Canadian Securities Laws. Except as set forth above, prior to the Closing Date and any Option Closing Date, the Company shall not issue any press release or other communication directly or indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise, earnings or business affairs, except for routine communications in the ordinary course of business consistent with past practice, without the prior written consent of the Representative, which consent shall not be unreasonably withheld, conditioned or delayed.

 

3.20No Fiduciary Duties. The Company acknowledges and agrees that the Underwriters’ responsibility to the Company is solely contractual in nature and that none of the Underwriters or their affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions contemplated by this Agreement. Notwithstanding anything in this Agreement to the contrary, the Company acknowledges that the Underwriters may have financial interests in the success of the Offering that are not limited to the difference between the price to the public and the purchase price paid to the Company by the Underwriters for the Offered Shares and the Underwriters have no obligation to disclose, or account to the Company for, any of such additional financial interests. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any breach or alleged breach of fiduciary duty.

 

31

 

 

3.21Company Lock-Up Agreements.

 

3.21.1Restriction on Sales of Securities. The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent of the Representative, it will not, for a period of four (4) months following the Closing Date (the “Lock-Up Period”): (a) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any Common Shares or securities convertible into or exercisable or exchangeable for Common Shares; (b) file or cause to be filed any registration statement with the Commission relating to the offering of Common Shares or securities convertible into or exercisable or exchangeable for Common Shares; (c) complete any offering of debt securities of the Company, other than entering into a line of credit with a traditional bank; or (d) enter into any swap or other arrangement that transfers to another, in whole or in part, the economic consequences of ownership of Common Shares, whether any transaction described in clause (a), (b), (c), or (d) is to be settled by delivery of Common Shares or other securities, in cash or otherwise. The restrictions contained in this Section shall not apply to: (i) the Offered Shares and Agent Securities to be issued or sold hereunder; (ii) the issuance of Common Shares upon exercise of a stock option or warrant or conversion of a security outstanding on the date hereof and disclosed in the Offering Documents; (iii) stock option, restricted share unit, performance share unit or other equity awards granted under the Company’s equity incentive plans in the ordinary course of business or the filing of a registration statement on Form S-8 or any other registration statement covering Common Shares underlying such awards or otherwise issued as awards during the Lock-Up Period; (iv) securities issued as consideration in connection with a merger, acquisition or strategic transaction; (v) project-level or strategic financings; (vi) the filing (but not use for any distribution during the Lock-Up Period) of a successor or replacement short form base shelf prospectus; (vii) any registration statement contemplated by the Offering and this Agreement or the Agent Warrant Agreements; (viii) the Excluded Shares and securities issued in connection with the Flow acquisition, the related pre-Closing reorganization, the vendor take-back note or the related acquisition financing, in each case to the extent disclosed in the Offering Documents; (ix) the entry into, amendment, modification, refinancing, or incurrence of indebtedness under any lending arrangement with one or more commercial banks, institutional lenders, Ascent Partners Fund LLC, The K2 Principal Fund L.P., Fattore Glen, Orion Infrastructure Capital, RI Flow LLC, Ascent Partners LLC, eCapital Corp., NFS Leasing Canada Ltd., AB InBev or their respective affiliates, in the ordinary course of business, provided that such indebtedness or facility is not convertible into, exercisable or exchangeable for, and does not otherwise involve the issuance of, shares of Common Shares or any securities convertible into or exercisable or exchangeable for Common Shares ; (x) following good faith discussions and consultations with the Underwriters, registering for resale the Common Shares issuable upon exercise of the investor warrants held by Orion Infrastructure Capital and Ascent Partners Fund LLC; (xi) issuing to RI Flow Sub LLC (or its designee), in consideration for the certain loan amendments disclosed to the Underwriters in writing, warrants to purchase Common Shares having an aggregate value of US$3,000,000 with an exercise price equal to or greater than the market price of the Common Shares at the time of issuance (the "RI Warrants"), and issuing Common Shares upon exercise of the RI Warrants; or (xii) the entry into, amendment, modification or taking of any action in connection an equity line of credit entered into by the Company or any successor to or Subsidiary of the Company with the Representative as placement agent (an “ELOC” and the foregoing clauses (i) through (xii), collectively, the “Permitted Exceptions”).

 

3.21.2Restriction on Continuous Offerings. During the Lock-Up Period, the Company shall not, without the prior written consent of the Representative, directly or indirectly undertake an “at-the-market” or other continuous equity offering, except to the extent expressly permitted under Section 3.21.1. For greater certainty, this Section does not extend the Lock-Up Period beyond the four-month period specified in Section 3.21.1.

 

32

 

 

3.21.3Restriction on Variable Rate Transactions. From the date hereof until the four (4)-month anniversary of the Closing Date, without the prior consent of the Representative, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Shares or securities exercisable or exchangeable for or convertible into Common Shares (or a combination of units thereof) involving a Variable Rate Transaction. “Variable Rate Transaction” means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive, additional Common Shares either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations for the Common Shares at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Shares or (ii) enters into, or effects a transaction under, any agreement (other than an ELOC) whereby the Company may issue securities at a future determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether such agreement is subsequently canceled, in each case, other than the Permitted Exceptions. This Section will not apply to the Excluded Shares, an ELOC or to any conversion, exercise, reset or other adjustment under or in respect of the convertible notes, warrants, standstill agreements, conversion agreements or amending agreements identified on Schedule 5 or otherwise disclosed in the Offering Documents. Any Underwriter shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.

  

3.21.4Release of D&O Lock-up Period. If the Representative, in its discretion, agrees to release or waive the restrictions set forth in a Lock-Up Agreement for an officer or director of the Company and provides the Company with notice of the impending release or waiver at least three Business Days before its effective date, the Company agrees to announce the impending release or waiver by a press release substantially in the form of Exhibit B through a major news service at least two Business Days before the effective date of the release or waiver.

 

3.21.5Blue Sky Qualifications. The Company shall use its commercially reasonable efforts, in cooperation with the Underwriters, if necessary, to qualify the Offered Shares and any Agent Securities required to be qualified for offering and sale under the applicable securities laws of such states and other jurisdictions as the Company and the Representative may agree in writing, and to maintain such qualifications in effect so long as required to complete the distribution of such securities; provided, however, that the Company shall not be obligated to file any general consent to service of process, qualify as a foreign corporation or dealer in securities in a jurisdiction in which it is not so qualified, or subject itself to taxation in respect of doing business in a jurisdiction in which it is not otherwise so subject.

 

3.21.6Reporting Requirements. The Company, during the period when a prospectus relating to the Offered Shares is (or, but for Rule 172, would be) required to be delivered under the Securities Act, shall file all documents required to be filed with the Commission pursuant to the Exchange Act within the required time periods (including any applicable extensions obtained thereby).

 

3.21.7Emerging Growth Company Status. The Company shall promptly notify each Underwriter if the Company ceases to be an Emerging Growth Company at any time prior to the later of: (i) completion of the distribution of the Offered Shares within the meaning of the Securities Act; and (ii) fifteen days following completion of the Lock-Up Period.

 

3.21.8IRS Forms. Each Underwriter shall deliver to the Company (or its agent), at or before the Closing Date, a properly completed and executed Internal Revenue Service (“IRS”) Form W-9 or an IRS Form W-8, as appropriate, together with all required attachments to such form, and such other forms, certificates or waivers as the Company may reasonably request in order to establish an exemption from or reduced rate of withholding under the Income Tax Act (Canada), including any waiver under Regulation 105 thereof.

 

33

 

 

4.Conditions of Underwriters’ Obligations.

 

The obligations of the Underwriters to purchase and pay for the Offered Shares shall be subject to (i) the continuing accuracy of the representations and warranties of the Company applicable to such Underwriter in its applicable capacity as of the date hereof and as of the Closing Date and the Option Closing Date, if any; (ii) the accuracy of the statements of officers of the Company made pursuant to the provisions hereof; (iii) the performance by the Company of its obligations hereunder applicable to the relevant tranche; and (iv) the following conditions, in each case to the extent applicable to the relevant tranche:

 

4.1Regulatory Matters.

 

4.1.1Effectiveness of Registration Statement. The Registration Statement has become effective not later than 5:00 p.m., Eastern time, on the date of this Agreement or such later date and time as shall be consented to in writing by the Underwriters, and, on each of the Closing Date and any Option Closing Date, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto shall have been issued under the Securities Act, no order preventing or suspending the use of the U.S. Preliminary Prospectus or the U.S. Final Prospectus shall have been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company’s knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information.

 

4.1.2No Cease Trade Order; LIFE Compliance. On each of the Closing Date and any Option Closing Date, no cease trade order shall have been issued by any Canadian Securities Regulator and no proceedings for such purpose, to the knowledge of the Company, shall be pending or threatened and the Company shall have satisfied all conditions applicable to the Company's reliance on the LIFE Exemption and shall have filed or issued, as applicable, the LIFE News Release, LIFE Offering Document and any required LIFE Offering Document Amendment in accordance with Canadian Securities Laws.

 

4.1.3FINRA Clearance. On or before the date of this Agreement, the Representative shall have received, directly or through Underwriters’ Counsel, correspondence from FINRA stating that FINRA will raise no objection to the amount of compensation allowable or payable to the Underwriters as described in the Registration Statement.

 

4.1.4Exchange Approvals. On the Closing Date: (i) the Offered Shares and the Underlying Common Shares, as applicable, shall have been conditionally approved or approved for listing on Nasdaq and Cboe, as applicable, subject only to customary conditions, satisfaction of post-Closing filing requirements and official notice of issuance, where applicable; (ii) no applicable Exchange shall have objected to the Offering or the issuance or listing of the applicable securities; and (iii) the Company shall have delivered to the Representative copies of the applicable conditional approval or approval letters or emails. On each Option Closing Date, the Option Shares issued on that Option Closing Date shall have been approved for listing on Nasdaq and Cboe, as applicable, subject only to customary conditions and official notice of issuance.

 

4.2Company Counsel Matters.

 

4.2.1Closing Date Opinion of U.S. Counsel. On the Closing Date, the Representative shall have received the favorable opinion of Alston & Bird LLP, U.S. counsel to the Company, and a written statement providing customary “10b-5” negative assurances, dated the Closing Date and addressed to the Underwriters, in form and substance reasonably satisfactory to counsel for the Underwriters.

 

4.2.2Closing Date Opinion of Canadian Counsel. On the Closing Date, the Representative shall have received the favorable opinion of Bennett Jones LLP, Canadian legal counsel to the Company, dated the Closing Date and addressed to the Underwriters, as to customary corporate and securities law matters, in form and substance reasonably satisfactory to counsel for the Underwriters and containing customary assumptions and exclusions.

 

4.2.3Option Closing Date Opinions of Counsel. On each Option Closing Date, if any, the Representative shall have received the favorable opinions of each counsel listed in Sections 4.2.1 and 4.2.2, dated the applicable Option Closing Date, addressed to the Underwriters and in form and substance reasonably satisfactory to the Representative, confirming as of the Option Closing Date the statements made in the opinions delivered on the Closing Date, in each case to the extent relevant to the Option Shares and that Option Closing Date.

 

34

 

 

4.2.4Reliance. In rendering such opinions, counsel may rely: (i) as to matters involving the application of laws other than the laws of the United States and Canada and the jurisdictions in which they are admitted, upon opinions of other counsel reasonably acceptable to the Representative; and (ii) as to matters of fact, upon certificates or other written statements of officers of the Company and public officials. Copies of such statements, certificates and reliance opinions shall be delivered to Underwriters’ Counsel upon request. The opinions delivered pursuant to this Section may be relied upon by each Underwriter and Underwriters’ Counsel.

 

4.3Comfort Letters.

 

4.3.1Cold Comfort Letter. At the time this Agreement is executed, the Representative shall have received a cold comfort letter from the Auditor containing statements and information of the type customarily included in accountants’ comfort letters with respect to the financial statements and certain financial information contained or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents, addressed to the Underwriters and in form and substance reasonably satisfactory to the Representative and the Auditor, dated as of the date of this Agreement.

 

4.3.2Bring-down Comfort Letter. At the Closing Date and each Option Closing Date, if any, the Representative shall have received from the Auditor a letter, addressed to the Underwriters and dated as of the applicable Closing Date or Option Closing Date, reaffirming the statements made in the letter furnished pursuant to Section 4.3.1, except that the specified date referred to therein shall be a date not more than three Business Days prior to the applicable Closing Date or Option Closing Date.

 

4.4Officers’ Certificates.

 

4.4.1Officers’ Certificate. The Company shall have furnished to the Representative a certificate, dated the Closing Date or Option Closing Date, as applicable, signed by its Chief Executive Officer and Chief Financial Officer, stating that: (i) such officers have carefully examined the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents and the LIFE Offering Documents; (ii) the representations and warranties of the Company in this Agreement applicable as of that date are true and correct in all material respects; (iii) the Company has complied in all material respects with all obligations and satisfied all conditions required to be performed or satisfied by it at or before that date; and (iv) there has not been any Material Adverse Change except as disclosed in the applicable Offering Documents.

 

4.4.2Secretary’s Certificate. At the Closing Date and each Option Closing Date, the Representative shall have received a certificate of the Company signed by the Secretary of the Company and dated as of the applicable date, certifying: (i) that the Articles and similar governing documents are true and complete, have not been modified and remain in full force and effect; (ii) that the resolutions of the Board relating to the Offering, the issuance of the Offered Shares and the issuance of the Agent Securities, are in full force and effect and have not been modified; (iii) as to the accuracy and completeness of all correspondence between the Company or its counsel and the Canadian Securities Regulators, the Commission and the applicable Exchanges, as applicable; (iv) the good standing and foreign qualification of the Company and its Subsidiaries; and (v) the incumbency of the officers of the Company. The documents referred to in the certificate shall be attached thereto.

 

4.4.3Chief Financial Officer’s Certificate. At the time this Agreement is executed, the Closing Date and each Option Closing Date, the Representative shall have received a certificate of the Company signed by the Chief Financial Officer of the Company, in each case, in form satisfactory to the Representative, addressed to the Underwriters, and of the same tenor as the letters referred to in Section 4.3 of this Agreement with respect to certain financial or other quantitative information contained or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents.

 

35

 

 

4.5No Material Changes. Prior to and on each of the Closing Date and each Option Closing Date, if any: (i) there shall have been no Material Adverse Change or development that would reasonably be expected to result in Material Adverse Change in the condition or the business activities, financial or otherwise, of the Company, or any of its Subsidiaries, from the latest dates as of which such condition is set forth in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents; (ii) no action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company or any director or officer before or by any court or federal, state or provincial commission, board or other administrative agency wherein an unfavorable decision, ruling or finding would reasonably be expected to result in a Material Adverse Change, except as set forth in the Registration Statement, the Time of Sale Prospectus and the Final Offering Documents; (iii) no stop order shall have been issued under the Securities Act and no proceedings therefor shall have been initiated or threatened by the Commission; (iv) no cease trade order shall have been issued by any Canadian Securities Regulator; (v) no action shall have been taken and no law, statute, rule, regulation or order shall have been enacted, adopted or issued by any Governmental Entity which would prevent the issuance or sale of the Offered Shares or result in a Material Adverse Change; (vi) no injunction, restraining order or order of any other nature by any federal, state or provincial court of competent jurisdiction shall have been issued which would prevent the issuance or sale of the Offered Shares or result in a Material Adverse Change; and (vii) the Registration Statement, the Time of Sale Prospectus and the U.S. Final Prospectus and any amendments or supplements thereto shall contain all material information which is required to be stated therein in accordance with the Securities Act and the Securities Act Regulations and shall conform in all material respects to the requirements of the Securities Act and the Securities Act Regulations, and neither the Registration Statement, the Time of Sale Prospectus nor the Final Offering Documents nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

4.6Delivery of Agreements.

 

4.6.1Lock-Up Agreements. On or before the date of this Agreement, the Company shall have delivered to the Representative executed copies of the Lock-Up Agreements from each person listed in Schedule 4. Each Lock-Up Agreement shall be expressly in favour of the Representative, and no release or waiver shall be effective without the prior written consent of the Representative.

 

4.6.2Agent Warrant Agreement. On the Closing Date and each Option Closing Date, if applicable, the Company shall have delivered directly to the Representative executed Agent Warrant Agreements evidencing the Agent Warrants issuable on that date in accordance with this Agreement.

 

4.7Additional Documents. On the Closing Date and each Option Closing Date, if any, the Representative and Underwriters’ Counsel shall have been furnished with such documents, certificates and opinions as they may reasonably require to: (i) permit Underwriters’ Counsel to provide customary advice or opinions to the Underwriters; (ii) evidence the accuracy of the representations and warranties applicable as of that date; (iii) evidence fulfillment of the applicable conditions contained herein; and (iv) confirm the valid issuance and delivery of the Firm Shares, Option Shares and Agent Securities, as applicable. All proceedings taken by the Company in connection with the issuance and sale of the applicable Offered Shares and the issuance of the applicable Agent Warrants shall be reasonably satisfactory in form and substance to the Representative and Underwriters’ Counsel.

 

36

 

 

5.Indemnification.

 

5.1Indemnification of the Underwriters.

 

5.1.1General. The Company agrees to indemnify and hold harmless each Underwriter, in its respective capacity as an Underwriter, its affiliates, each Selling Firm and each of its and their respective directors, officers, members, employees, representatives, partners and agents and each person, if any, who controls any such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively, the “Underwriter Indemnified Parties,” and each, a “Underwriter Indemnified Party”), against any and all loss, liability, claim, judgment, assessment, damage and expense whatsoever, including any and all legal or other expenses reasonably incurred in investigating, preparing for, pursuing or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between any Underwriter Indemnified Party and the Company or between any Underwriter Indemnified Party and any third party, or otherwise, to which any Underwriter Indemnified Party may become subject under the Securities Act, the Exchange Act, Canadian Securities Laws, any other statute, at common law or otherwise or under the laws of any foreign jurisdiction (each, a “Claim”): (a) arising out of or based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in: (A) the Registration Statement, the Time of Sale Prospectus, the Preliminary Offering Documents, the Final Offering Documents, the LIFE Offering Document, any LIFE Offering Document Amendment or the LIFE News Release approved by the Company, in each case as from time to time amended or supplemented; (B) any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the Offering, including any Road Show or investor presentation made to investors by the Company, whether in person or electronically; or (C) any application, report, filing or other document or written communication executed by the Company or based upon written information furnished by the Company and filed with the Commission, any Canadian Securities Regulator, any applicable state securities commission or agency, FINRA or any applicable Exchange, or used in any jurisdiction in order to register, qualify or obtain an exemption for the offer or sale of any Offered Shares or Agent Securities; (ii) the omission or alleged omission from any document or communication referred to in clause (a)(i) of a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading; (iii) any Misrepresentation or alleged Misrepresentation contained in any LIFE Offering Document, LIFE Offering Document Amendment or LIFE News Release approved by the Company; or (iv) any breach by the Company of any representation, warranty, covenant or agreement contained in this Agreement; and (b) otherwise arising out of, based upon or in connection with the Offering, the engagement of any Underwriter or the performance by an Underwriter of its services in its capacity as an Underwriter under this Agreement; provided, however, that the Company shall not be liable under clauses (a)(i), (a)(ii) or (a)(iii) to the extent that any such Claim arises out of or is based upon an untrue statement, omission or Misrepresentation made in reliance upon and in conformity with Underwriter Information furnished by the particular Underwriter Indemnified Party seeking indemnification; provided further, however, that the Company shall not be liable under this Section 5.1.1 for any all loss, liability, claim, judgment, assessment, damage and expense whatsoever, including any and all legal or other expenses reasonably incurred in investigating, preparing for, pursuing or defending against any litigation, commenced or threatened, or any claim whatsoever, (x) if the foregoing is determined by a court of competent jurisdiction to have resulted from any Underwriter’s gross negligence, bad faith or willful misconduct or (y) by the Company against any Underwriter. The Company also agrees that it will reimburse each Underwriter Indemnified Party for all fees and expenses, including any and all legal or other expenses reasonably incurred in investigating, preparing for, pursuing or defending against any litigation, commenced or threatened, or any Claim whatsoever, whether arising out of any action between any Underwriter Indemnified Party and the Company or between any Underwriter Indemnified Party and any third party, or otherwise (collectively, the “Expenses”), and further agrees, wherever and whenever reasonably possible, to advance payment of Expenses as they are incurred by an Underwriter Indemnified Party in investigating, preparing for, pursuing or defending any Claim, subject to an undertaking by such Underwriter Indemnified Party to repay amounts so advanced if it is finally judicially determined that such Underwriter Indemnified Party was not entitled to indemnification under this Section 5.1; provided that the Company shall not be responsible for the fees of more than one law firm representing the Underwriter Indemnified Parties in any jurisdiction.

 

37

 

 

5.1.2Procedure. If any action, suit, proceeding, inquiry or investigation is commenced, or any Claim is asserted, against an Underwriter Indemnified Party in respect of which indemnification may be sought against the Company pursuant to Section 5.1.1, such Underwriter Indemnified Party shall promptly notify the Company in writing of the commencement or assertion thereof; provided that the failure to provide such notice shall not relieve the Company of any obligation or liability that the Company may have under this Section 5 or otherwise, except to the extent the Company is materially prejudiced by that failure. The Company shall be entitled to assume the defence of such Claim, including the employment of counsel reasonably satisfactory to the affected Underwriter Indemnified Party and payment of the reasonable fees and expenses of such counsel. The affected Underwriter Indemnified Party shall have the right to participate in the defence of such Claim through counsel of its own choice. The reasonable fees and expenses of separate counsel for the affected Underwriter Indemnified Party shall be paid by the Company if: (i) the Company has failed to assume the defence of the Claim within a reasonable time after receiving notice thereof; (ii) the affected Underwriter Indemnified Party has been advised by counsel that an actual or potential conflict of interest exists between the Company and such Underwriter Indemnified Party in the conduct of the defence; (iii) the Company and such Underwriter Indemnified Party may have different or additional defences available to them; or (iv) the Company has authorized the affected Underwriter Indemnified Party to retain separate counsel at the Company’s expense; provided that the Company shall not be responsible for the fees of more than one law firm representing the Underwriter Indemnified Parties in any jurisdiction. The Company shall not be liable for the fees and expenses of more than one separate firm of counsel for all Underwriter Indemnified Parties affected by substantially the same Claim in each applicable jurisdiction, unless an actual or potential conflict exists among such Underwriter Indemnified Parties as documented in the reasonable opinion of counsel thereto; . The Company shall not be liable for any settlement of a Claim effected by an Underwriter Indemnified Party without the Company’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. The Company shall not, without the prior written consent of each affected Underwriter Indemnified Party, settle, compromise or consent to the entry of any judgment in, or otherwise seek to terminate, any pending or threatened Claim in respect of which advancement, reimbursement, indemnification or contribution may be sought under this Section 5, whether or not an affected Underwriter Indemnified Party is a party thereto, unless such settlement, compromise, consent or termination: (a) includes an unconditional release of each affected Underwriter Indemnified Party, in form and substance reasonably satisfactory to each such Underwriter Indemnified Party, from all liabilities, expenses and Claims arising out of or relating to such Claim; and (b) does not include any statement as to or admission of fault, culpability, liability or failure to act by or on behalf of any Underwriter Indemnified Party. No consent, settlement, compromise, release or waiver by one Underwriter or any Underwriter Indemnified Party affiliated with that Underwriter shall bind any other Underwriter or any Underwriter Indemnified Party affiliated with such other Underwriter.

 

5.2Indemnification of the Company. Each Underwriter agrees to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively, the “Company Indemnified Parties,” and each, a “Company Indemnified Party”), against any and all loss, liability, claim, judgment, assessment, damage and expense described in Section 5.1.1, as incurred, but only to the extent arising out of or based upon: (a) an untrue statement or omission, or alleged untrue statement or omission, made in the Registration Statement, any Preliminary Offering Document, the Time of Sale Prospectus, any Final Offering Document or any amendment or supplement thereto, in reliance upon and in strict conformity with Underwriter Information furnished by such Underwriter expressly for inclusion therein; or (b) a Misrepresentation or alleged Misrepresentation contained in a LIFE Offering Document, LIFE Offering Document Amendment or LIFE News Release, in reliance upon and in strict conformity with Underwriter Information furnished by such Underwriter expressly for inclusion therein; provided, however, that in no event shall any Underwriter be liable under this Section 5.2 for any amount in excess of the underwriting discounts, commissions and agency fees actually received by such Underwriter in connection with the applicable tranche of the Offering. No Underwriter shall have any indemnification obligation under this Section 5.2 in respect of information furnished by any other Underwriter or any act, omission, conduct or information attributable solely to any other Underwriter. If any Claim is brought against a Company Indemnified Party in respect of which indemnification may be sought against an Underwriter under this Section 5.2, such Underwriter shall have the rights and obligations given to the Company under Section 5.1.2, and each Company Indemnified Party shall have the rights and obligations given to an Underwriter Indemnified Party under Section 5.1.2, with any necessary conforming changes. The Company shall promptly notify each affected Underwriter of the commencement of any Claim against a Company Indemnified Party in connection with the issuance, offer or sale of the Offered Shares or Agent Securities or in connection with any Prospectus Offering Document, LIFE Offering Document, LIFE Offering Document Amendment or LIFE News Release.

 

38

 

 

5.3Contribution.

 

5.3.1Contribution Rights. If the indemnification provided for in Section 5.1 or Section 5.2 is for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of any loss, liability, claim, judgment, assessment, damage or expense, or any action in respect thereof, referred to therein, other than by reason of an express exception contained in Section 5.1 or Section 5.2, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid or payable by such indemnified party as a result of such loss, liability, claim, judgment, assessment, damage or expense, or action in respect thereof: (a) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the applicable Underwriter or Underwriters, on the other hand, from the applicable tranche of the Offering; or (b) if the allocation provided by clause (a) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (a), but also the relative fault of the Company, on the one hand, and the applicable Underwriter or Underwriters, on the other hand, in connection with the statements, omissions, Misrepresentations, acts or conduct that resulted in such loss, liability, claim, judgment, assessment, damage or expense, together with any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the applicable Underwriter or Underwriters, on the other hand, from the applicable tranche of the Offering shall be deemed to be in the same respective proportions as: (i) the aggregate net proceeds of the applicable tranche received by the Company, before deducting expenses, bear to (ii) the aggregate underwriting discounts, commissions, agency or placement fees and other compensation actually received by the applicable Underwriter or Underwriters in respect of such tranche. For greater certainty, the relative benefits in respect of the Offering shall be determined by reference to the net proceeds received by the Company from the sale of the Offered Shares and the underwriting discounts, commissions and other compensation received by the applicable Underwriter or Underwriters. The relative fault of the Company, on the one hand, and each applicable Underwriter, on the other hand, shall be determined by reference to, among other things, whether the untrue statement, omission or Misrepresentation relates to information supplied by the Company or by the applicable Underwriter, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement, omission or Misrepresentation. The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 5.3.1 were determined by pro rata allocation, even if the Underwriters were treated as one entity for such purpose, or by any other method of allocation that does not take into account the equitable considerations referred to in this Section 5.3.1. The amount paid or payable by an indemnified party as a result of a loss, liability, claim, judgment, assessment, damage or expense, or action in respect thereof, referred to in this Section 5.3.1 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating, preparing for, pursuing or defending any such action or claim. Notwithstanding the provisions of this Section 5.3.1, no Underwriter shall be required to contribute any amount in excess of the amount by which the aggregate underwriting discounts, commissions, agency or placement fees and other compensation actually received by such Underwriter in connection with the applicable portion of the Offering exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of the applicable untrue or alleged untrue statement, omission or alleged omission, or Misrepresentation or alleged Misrepresentation. No person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act, or found liable for fraud under applicable Canadian Securities Laws, shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation or fraud. Each Underwriter’s obligation to contribute pursuant to this Section 5.3 is several and not joint. No Underwriter shall have any obligation to contribute in respect of any act, omission, information or conduct attributable solely to any other Underwriter.5.3

 

5.3.2Contribution Procedure. Within fifteen (15) days after receipt by any party to this Agreement, or its representative, of notice of the commencement of any action, suit or proceeding, such party shall, if a claim for contribution in respect thereof is to be made against another party (the “Contributing Party”), notify the Contributing Party in writing of the commencement thereof; provided that failure to provide such notice shall not relieve the Contributing Party from any liability it may have other than for contribution under this Section 5.3.2, except to the extent the Contributing Party is materially prejudiced by that failure. If any such action, suit or proceeding is brought against a party and such party notifies a Contributing Party of the commencement thereof within the foregoing period, the Contributing Party shall be entitled to participate in such action, suit or proceeding with the notifying party and any other Contributing Party similarly notified. A Contributing Party shall not be liable to a party seeking contribution on account of any settlement of a claim, action or proceeding effected by the party seeking contribution without the prior written consent of the Contributing Party, which consent shall not be unreasonably withheld, conditioned or delayed. The contribution provisions contained in this Section 5.3 are intended to supersede, to the extent permitted by applicable law, any right to contribution otherwise available under the Securities Act, the Exchange Act, Canadian Securities Laws or otherwise.

 

39

 

 

5.4Survival; Other Rights; No Duplicate Recovery. The indemnification, advancement, reimbursement and contribution obligations set forth in this Section 5 shall remain operative and in full force and effect notwithstanding: (i) any investigation made by or on behalf of any Underwriter, any Underwriter Indemnified Party, the Company, any Company Indemnified Party or any person controlling any of them; (ii) acceptance of any Offered Shares or Agent Securities and payment therefor; (iii) any termination of this Agreement; or (iv) the completion of the Offering. The rights provided in this Section 5 are in addition to, and not in limitation of, any indemnification, advancement, reimbursement, contribution or other rights that expressly survive under the Engagement Letter, provided that no indemnified party shall be entitled to duplicative recovery in respect of the same loss, liability, claim, damage or expense. Each Underwriter holds its rights under this Section 5 separately and solely for itself and its respective Underwriter Indemnified Parties. No Underwriter may exercise, waive, amend, settle, release or otherwise affect any right under this Section 5 belonging to any other Underwriter or any Underwriter Indemnified Party affiliated with such other Underwriter without the prior written consent of such other Underwriter.

 

6.Default by an Underwriter.

 

6.1Default Not Exceeding 10% of Firm Shares or Option Shares. If any Underwriter or Underwriters shall default in its or their obligations to purchase the Firm Shares or the Option Shares, if the Over-Allotment Option is exercised hereunder, and if the number of the Firm Shares or Option Shares with respect to which such default relates does not exceed in the aggregate 10% of the number of Firm Shares or Option Shares that all Underwriters have agreed to purchase hereunder, then such Firm Shares or Option Shares to which the default relates shall be purchased by the non-defaulting Underwriters in proportion to their respective commitments hereunder as set forth in Schedule 1 or in such other proportions as the Representative may determine.

 

6.2Default Exceeding 10% of Firm Shares or Option Shares. In the event that the default addressed in Section 6.1 relates to more than 10% of the Firm Shares or Option Shares, the Representative may in its discretion arrange for one or more non-defaulting Underwriters or another party or parties to purchase such Firm Shares or Option Shares to which such default relates on the terms contained herein. If, within two (2) Business Days after such default relating to more than 10% of the Firm Shares or Option Shares, the Representative does not arrange for the purchase of such Firm Shares or Option Shares, the Company shall be entitled to a further period of one (1) Business Day within which to procure another party or parties reasonably satisfactory to the Representative to purchase such Firm Shares or Option Shares on the terms contained herein. In the event that neither the Representative nor the Company arrange for the purchase of the Firm Shares or Option Shares to which a default relates as provided in this Section 6, this Agreement will automatically be terminated with respect to the Offering by written notice from the Representative or the Company without liability on the part of the Company, except as provided in Sections 5, 7.5 (other than with respect to any defaulting Underwriter), 7.7, 7.8, 8.1, 8.3 through 8.7 and 8.9 through 8.13, or the several Underwriters, except as provided in Section 5; provided, however, that if such default occurs with respect to the Option Shares, this Agreement will not terminate as to the Firm Shares; and provided, further, that nothing herein shall relieve a defaulting Underwriter of its liability, if any, to the other Underwriters and to the Company for damages occasioned by its default hereunder.

 

40

 

 

6.3Postponement of Closing Date. In the event that the Firm Shares or Option Shares to which the default relates are to be purchased by the non-defaulting Underwriters, or are to be purchased by another party or parties as aforesaid, such non-defaulting Underwriter(s) or the Company shall have the right to postpone the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding five (5) Business Days, in order to effect whatever changes may thereby be made necessary in the Registration Statement, the Time of Sale Prospectus or the Prospectus Offering Documents or in any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration Statement, the Time of Sale Prospectus or the Prospectus Offering Documents that in the opinion of Underwriters’ Counsel may thereby be made reasonably necessary. The term “Underwriter” as used in this Agreement shall include any party substituted under this Section 6 with like effect as if it had originally been a party to this Agreement with respect to such Offered Shares, unless the Representative expressly agrees otherwise in writing and, provided that all applicable dealer-registration and other regulatory requirements are satisfied.

 

7.Additional Covenants.

 

7.1Right of First Refusal. The Representative shall have an irrevocable right of first refusal, for a period of twelve (12) months from the later of the Listing and the Closing Date, to act as investment banker, book-running manager, placement agent, underwriter or financial advisor, as applicable, with respect to each U.S. public or private equity (including any equity line of credit and any at-the-market offering), equity-linked or convertible debt offering by the Company or any successor to or Subsidiary of the Company during such twelve (12)-month period, in each case on compensation terms customary to the Representative and acceptable to the Company, acting reasonably (the “Right of First Refusal”). The Representative shall have the sole right to determine whether any other broker-dealer shall participate in any such offering. If the Company proposes to pursue a transaction subject to the Right of First Refusal (a “Subject Transaction”), the Company shall provide the Representative with written notice describing the material terms of the proposed Subject Transaction. The Representative shall have five (5) days following receipt of such notice to notify the Company in writing whether it elects to exercise its Right of First Refusal with respect to the Subject Transaction. If the Representative does not exercise or elects not to exercise its Right of First Refusal within such five (5)-day period, including by failure to respond to the Company’s notice thereto of such Subject Transaction during that time period, the Representative shall have no further right with respect to that particular Subject Transaction; provided that the material terms of the Subject Transaction are not amended in a manner materially more favourable to the proposed investment banker, financial advisor, book-runner, underwriter or placement agent than the terms described in the notice delivered to the Representative. Failure to exercise the Right of First Refusal with respect to one Subject Transaction shall not affect the Representative’s Right of First Refusal with respect to any other Subject Transaction during the applicable period. For greater certainty, the Right of First Refusal shall not apply to: (i) financings conducted primarily in Canada, including any prospectus offering, private placement or other financing conducted under Canadian securities laws; (ii) project-level equity financings; (iii) project-level debt financings; (iv) traditional banking debt facilities; (v) mergers and acquisitions transactions; or (vi) project-level joint ventures, in each case unless otherwise agreed in writing by the Company and the Representative.

 

7.1.1Equity Line of Credit. Without limiting the foregoing, the Right of First Refusal shall apply to any ELOC entered into during the period of the Right of First Refusal. If the Representative exercises its Right of First Refusal with respect to an ELOC, then, notwithstanding the compensation terms otherwise referred to in Section 7.1, the Company shall pay the Representative a placement agent fee equal to one and a half percent (1.5%) of the gross proceeds of each drawdown under such ELOC. If the term of such ELOC extends beyond the expiry of the period of the Right of First Refusal, the Representative’s right to act as placement agent and to receive such fee shall continue solely with respect to an ELOC for the full remaining term of such ELOC, notwithstanding the expiry of the period of the Right of First Refusal. If such ELOC is replaced by a new equity line of credit with the same provider (or any affiliate of such provider), the Representative’s right to act as placement agent and to receive such fee shall continue solely with respect to such new equity line of credit for its full term, whether or not the period of the Right of First Refusal has expired at the time of such replacement.

 

41

 

 

7.2Effective Date of this Agreement and Termination Thereof.

 

7.3Effective Date. This Agreement shall become effective upon execution and delivery of counterparts of this Agreement by the Company and the Representative (the “Effective Date”).

 

7.4Termination. The Representative shall have the right to terminate this Agreement, by notice to the Company, at any time prior to the Closing Date or, with respect to the Option Shares, any Option Closing Date: (i) if any domestic or international event or act or occurrence has materially disrupted, or in the Representative’s reasonable opinion will in the immediate future materially disrupt, general securities markets in the United States or Canada; (ii) if trading on Nasdaq or Cboe shall have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall have been required by FINRA, the Commission, any Canadian Securities Regulator, any applicable Exchange or any other Governmental Entity having jurisdiction, or if trading in any securities of the Company has been suspended or materially limited by the Commission, any Canadian Securities Regulator or any Exchange; (iii) if the United States or Canada shall have become involved in a new war or an increase in major hostilities, or if a material act of terrorism, national emergency or other calamity or crisis shall have occurred, that in the judgment of the Representative is material and adverse and makes it impracticable to market the applicable Offered Shares in the manner and on the terms described in the Time of Sale Prospectus, the Prospectus Offering Documents or LIFE Offering Documents, as applicable, or to enforce contracts for the sale of securities; (iv) if a banking moratorium has been declared by a New York State or federal authority or by any applicable Canadian federal or provincial authority; (v) if a moratorium on foreign exchange trading has been declared which materially adversely impacts the United States or Canadian securities markets; (vi) if the Company shall have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured, will, in the Representative’s opinion, make it inadvisable to proceed with the delivery of the Firm Shares on the Closing Date, as applicable, or the Option Shares on an Option Closing Date; (vii) if the Company is in material breach of any of its representations, warranties, covenants or agreements hereunder applicable to the Underwriters or the relevant Offered Shares; (viii) if the Representative shall have become aware after the date hereof of a Material Adverse Change in the condition or prospects of the Company, or an adverse material change in general market conditions, that in the Representative’s judgment would make it impracticable to proceed with the offering, sale or delivery of the applicable Offered Shares or to enforce contracts made by the Underwriters for the sale of the applicable Offered Shares; (ix) if any order, ruling, proceeding, condition or other circumstance prevents or suspends the Company’s reliance on the LIFE Exemption or the use of any LIFE Offering Document, and such matter has not been cured or waived to the extent legally capable of waiver; or (x) if the Registration Statement is not effective, a stop order is issued or threatened, or any other regulatory condition prevents completion of the Offering. A termination after the Closing Date relating only to an Option Closing Date shall not affect the completed Firm Share Closing. No termination under this Section 7.4 shall affect any accrued right or liability, any liability for a prior breach or default, or any provision that expressly survives termination.

 

7.5Expenses. Whether or not the Offering is completed, in addition to the Expense Allowance, the Company will pay all of the expenses of the Offering and all of the reasonable and documented costs and expenses (the “Underwriters’ Expenses”) incurred by the Underwriters in connection with the Offering including the fees and disbursements of Underwriters’ counsel; reasonable fees and disbursements of other applicable experts and advisors; reasonable expenses related to roadshows and marketing activities; filing fees; stock exchange fees; reasonable out-of-pocket expenses of the Underwriters (including, but not limited to, their travel expenses in connection with due diligence and marketing activities) and taxes on all of the foregoing, provided that the aggregate Underwriters’ Expenses payable by the Company will not exceed the maximums set out in the Engagement Letter. The Underwriters’ Expenses and applicable taxes thereon will be paid by the Company even if the transactions contemplated by this Agreement are not completed or this Agreement is terminated, unless failure of acceptance, or completion or termination is the result of a breach of this Agreement by the Underwriters. The Underwriters’ Expenses shall be payable as directed by the Underwriters at Closing. Nothing in this Section 7.5 shall increase aggregate compensation above the amount permitted by FINRA. The expense cap in this Section 7.5 shall not limit or impair the indemnification, advancement, reimbursement or contribution provisions of Section 5.

 

42

 

 

7.6Expenses on Termination. If this Agreement is terminated by the Underwriters in accordance with the provisions of Section 7.4 hereof, the Company shall reimburse the Underwriters for all of their reasonable and documented out of pocket expenses, including the reasonable and documented fees and disbursements of counsel for the Underwriters, on the terms set out in Section 7.5; provided however, that if this Agreement is terminated by the Company as a result of a default by an Underwriter under Section 6.2, the Company shall have no obligation to reimburse the out of pocket expenses of any Underwriters that have failed to purchase the Offered Shares that they have agreed to purchase hereunder.

 

7.7Survival of Indemnification. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Section 5 shall remain in full force and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms of this Agreement or any part hereof. The indemnification, advancement, reimbursement and contribution rights of each Underwriter and its Underwriter Indemnified Parties are separate. No Underwriter may waive, settle, release or otherwise affect any right under Section 5 belonging to the other Underwriter or any Underwriter Indemnified Party affiliated with the other Underwriter without the prior written consent of that other Underwriter.

 

7.8Representations, Warranties, Agreements to Survive. All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless of (i) any investigation made by or on behalf of any Underwriter in its capacity as an Underwriter, any affiliate or selling agent of such Underwriter, any Underwriter Indemnified Party, any person controlling any Underwriter, its officers or directors, or any person controlling the Company; or (ii) delivery of and payment for the Offered Shares. Without limiting the foregoing, Sections 5, 7.5, 7.6, 7.7, this 7.8, 8.1, 8.3 through 8.7 and 8.9 through 8.13 shall survive termination of this Agreement in accordance with their respective terms.

 

8.Miscellaneous.

 

8.1Notices. All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered or certified mail, return receipt requested), personally delivered, sent by e-mail, or facsimile transmission and confirmed, and shall be deemed given when so delivered, e-mailed or faxed and confirmed or if mailed, two (2) days after such mailing.

 

If to the Underwriters:

 

Joseph Gunnar & Co., LLC

1000 RXR Plaza

Uniondale, New York 11556

 

Attention: Stephan A. Stein, President and Chief Executive Officer

Email: [Redacted – Email Address]

 

with a copy, which shall not constitute notice, to:

 

Mintz LLP

200 Bay St, South Tower, Suite 2800

Toronto, Ontario M5J 2J3

 

Attention: Alexander Katznelson

Email: [Redacted – Email Address]

 

43

 

 

If to the Company:

 

Cizzle Brands Corporation

35 McCleary Court, Unit 21

Concord, Ontario L4K 3Y9

 

Attention: John Celenza, Chairman and Chief Executive Officer

Email: [Redacted – Email Address]

 

with a copy, which shall not constitute notice, to:

 

Bennett Jones LLP

3400 One First Canadian Place, P.O. Box 130

Toronto, Ontario M5X 1A4

 

Attention: Aaron E. Sonshine

Email: [Redacted – Email Address]

 

and to:

 

Alston & Bird LLP

227 W. Monroe Street, Suite 3900

Chicago, Illinois 60606

 

Attention: Alyse Sagalchik

Email: [Redacted – Email Address]

 

8.2Research Analyst Independence. The Company acknowledges that each Underwriter’s research analysts and research departments are required to be independent from its investment banking division and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the Offering that differ from the views of their investment banking division. The Company acknowledges that each Underwriter is a full service securities firm and as such from time to time, subject to applicable securities laws, rules and regulations, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the Company; provided, however, that nothing in this Section 8.2 shall relieve the Underwriter of any responsibility or liability it may otherwise bear in connection with activities in violation of applicable securities laws, rules or regulations.

 

8.3Headings. The headings contained herein are for the sole purpose of convenience of reference and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.

 

8.4Amendment. This Agreement may only be amended by a written instrument executed by each of the parties hereto. Notwithstanding the foregoing, an amendment affecting only a separate right, obligation or liability of one Underwriter may be made by the Company and that Underwriter if the amendment does not directly or indirectly increase any obligation or liability of, reduce or impair any right or protection of, alter any economic allocation owing to or otherwise bind the other Underwriter.

 

8.5Entire Agreement. This Agreement, together with the other agreements and documents delivered pursuant to or in connection with this Agreement, constitutes the entire agreement of the parties with respect to the subject matter hereof and thereof and supersedes all prior agreements and understandings of the parties, oral and written, with respect to that subject matter.

 

8.6Binding Effect; Third Party Rights. This Agreement shall inure to the benefit of and shall be binding upon the Company, each Underwriter, each Underwriter Indemnified Party and each Company Indemnified Party referred to in Section 5, and their respective successors, legal representatives and permitted assigns. Except as expressly provided in Section 5 , no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Agreement or any provision herein contained. The term “successors and assigns” shall not include a purchaser, in its capacity as such, of securities from any Underwriter.

 

44

 

 

8.7Governing Law; Consent to Jurisdiction; Trial by Jury. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without giving effect to conflict of laws principles thereof if the same would result in the application of the laws of another jurisdiction. Each of the parties hereto hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. Each of the parties hereto hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process or summons to be served upon a party hereto may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 8.1 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the receiving party in any action, proceeding or claim. The parties hereto each agree that the prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company, on its behalf and, to the extent permitted by applicable law, on behalf of its shareholders and affiliates, and each Underwriter, in each of its respective capacities under this Agreement, hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. Nothing in this Section limits the application of Canadian Securities Laws to the LIFE Exemption or any non-waivable statutory right or remedy of a Substituted Purchaser.

 

8.8Execution in Counterparts; Electronic Signatures. This Agreement may be executed in one or more counterparts and by the different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same agreement, and shall become effective when one or more counterparts have been signed by the Company and the Representative and delivered to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/PDF transmission or by electronic-signature platform shall constitute valid and sufficient delivery thereof. The Representative executes this Agreement for itself and as Representative of the other Underwriters, if any, named in Schedule 1 hereto.

 

8.9Waiver, etc. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment. Any action, consent or waiver of the Underwriters hereunder may be taken or given by the Representative on behalf of the Underwriters, and any such action, consent or waiver shall be binding upon the Underwriters.

 

8.10Judgment Currency. If, for the purpose of obtaining or enforcing judgment against the Company in any court, it is necessary to convert a sum due hereunder into any currency other than United States dollars, the parties agree, to the fullest extent permitted by law, that the rate of exchange used shall be the rate at which in accordance with normal banking procedures the applicable Underwriter could purchase United States dollars with such other currency in New York, New York on the Business Day preceding the day on which final judgment is given. The obligation of the Company with respect to any sum due from it to any Underwriter or any Underwriter Indemnified Party shall, notwithstanding any judgment in a currency other than United States dollars, not be discharged until the first Business Day following receipt by such person of any sum adjudged to be so due in such other currency, on which such person may in accordance with normal banking procedures purchase United States dollars with such other currency; if the United States dollars so purchased are less than the sum originally due, the Company agrees, as a separate obligation and notwithstanding any such judgment, to indemnify such person against such loss.

 

45

 

 

8.11Taxes; Withholding. All payments to be made by the Company to the Underwriters hereunder shall be made without withholding or deduction for or on account of any present or future taxes, duties or governmental charges imposed by Canada or any political subdivision or taxing authority thereof, unless the Company is compelled by law to deduct or withhold such amounts, in which case the Company shall pay such additional amounts as will result in receipt by each Underwriter of such amounts as would have been received had no such withholding or deduction been required; provided that no such additional amount will be payable to the extent the withholding or deduction arises from (i) the failure of an Underwriter to deliver the forms, certificates or waivers contemplated by Section 3.30 or otherwise reasonably requested by the Company in order to establish an exemption from or reduced rate of withholding, or (ii) taxes imposed on or measured by the net income or capital of an Underwriter, or any branch profits taxes.

 

8.12USA PATRIOT ACT. In accordance with the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients.

 

8.13Severability. If any provision of this Agreement is held to be invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect any other provision hereof, and this Agreement shall be construed as if such invalid or unenforceable provision had never been contained herein.

 

[Signature Page Follows]

 

46

 

 

If the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between us.

 

Very truly yours,  
   
CIZZLE BRANDS CORPORATION  
   
By: /s/ "John Celenza"  
  Name: John Celenza  
  Title: Chairman and Chief Executive Officer  

 

 

AGREED AND ACCEPTED:

 

JOSEPH GUNNAR & CO., LLC  
   
   
By: /s/ "Stephan A. Stein"  
  Name: Stephan A. Stein  
  Title: President & CEO
For itself and as Representative of the other Underwriters named in Schedule 1 hereto.
 

 

 

 

Schedule 1

 

Underwriting Commitments

 

Underwriter Number of Firm Shares to Be
Purchased
Number of Option Shares to Be
Purchased if the Over-Allotment
Option Is Fully Exercised
Joseph Gunnar & Co., LLC 3,030,000 454,500
TOTAL 3,030,000 454,500

 

 

 

Schedule 2
Pricing and Offering Information

 

Offering

 

Number of Firm Shares: 3,030,000

Number of Option Shares: 454,500

Public Offering Price per Offered Share: US$5.00

Underwriting Discount per Offered Share: US$0.325

Non-accountable Expense Allowance per Offered Share: US$0.05

Proceeds to the Company per Offered Share before accountable expenses: US$4.675

 

Common Information

 

Applicable Time: 4:45 pm Eastern time

Closing Date: November 23, 2026

Qualification Deadline: November 20, 2026

Canadian Selling Jurisdictions: Alberta, British Columbia, Ontario and Quebec.

Qualifying Jurisdictions: All of the provinces and territories of Canada

 

 

 

Schedule 3
President’s List

 

Investor Maximum
Approved
Investment
Applicable Cash
Fee
Applicable Agent
Warrant Percentage
N/A      

 

 

 

Schedule 4

Lock-Up Parties

 

Directors and Officers Required to Deliver Lock-Up Agreements

 

1.John Celenza

 

2.Steven Tschirhart

 

3.Anthony Mila

 

4.Blane Kaufman

 

5.Lauri Holomis

 

6.Nunziato Fattore

 

7.Ndamukong Suh

 

8.Michael Doolan

 

9.Geoff Bedford

 

10.David Giancoulos

 

11.Dominic Scarangella

 

Holders of 5% or More of the Outstanding Common Shares

 

1.John Celenza

 

2.Tucker Wright

 

 

 

Schedule 5

Excluded Shares

 

Holder or Related Party Instrument or
Arrangement
Maximum Rolled or
Converted Amount
Resulting Securities
Cliff Rucker, RI Flow Sub LLC and/or applicable affiliates or related entities Vendor take-back note N/A N/A
Ascent Partners Fund LLC Convertible note USD $1,680,216.80 331,802 Common Shares
The K2 Principal Fund L.P. Convertible note CAD$2,500,000 344,828 Common Shares
Fattore Glen Convertible note CAD$2,500,000 312,500 Common Shares

 

 

 

Exhibit A
Form of Lock-Up Agreement

 

See attached.

 

 

 

LOCK-UP AGREEMENT

 

[●], 2026

 

Joseph Gunnar & Co., LLC

1000 RXR Plaza, Uniondale, New York 11556

 

Re:      Proposed Offering by Cizzle Brands Corporation

 

Ladies and Gentlemen:

 

The undersigned, a shareholder, officer and/or director of Cizzle Brands Corporation, a corporation incorporated under the laws of the Province of British Columbia, Canada (the “Company”), understands that Joseph Gunnar & Co., LLC (the “Representative”), propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with the Company, providing for the offering (the “Offering”) of common shares of the Company (“Common Shares”). In recognition of the benefit that the Offering will confer upon the undersigned as a shareholder, an officer and/or a director of the Company, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with the Representative that, during the period beginning on the date hereof and ending on the date that is three (3) months following the Closing Date (as defined in the Underwriting Agreement) (the “Lock-Up Period”), the undersigned will not, without the prior written consent of the Representative, directly or indirectly, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, lend or otherwise dispose of or transfer any Common Shares or any securities convertible into or exchangeable or exercisable for Common Shares, whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the “Lock-Up Securities”), or exercise any right with respect to the registration of any of the Lock-Up Securities, or file or cause to be filed any registration statement in connection therewith, under the Securities Act of 1933, as amended (the “Securities Act”), or a prospectus or other public filing with any securities commission or securities regulatory authority in any province or territory of Canada (collectively, the “Canadian Securities Regulators”) or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of Common Shares or other securities, in cash or otherwise.

 

The undersigned agrees that the foregoing restrictions preclude the undersigned from engaging in any hedging or other transaction which is designed to or which reasonably could be expected to lead to or result in a sale or disposition of the Lock-Up Securities even if such securities would be disposed of by someone other than the undersigned. Such prohibited hedging or other transactions would include, without limitation, any short sale or any purchase, sale or grant of any right (including, without limitation, any put or call option) with respect to any of the Lock-Up Securities or with respect to any security that includes, relates to, or derives any significant part of its value from the Lock-Up Securities.

 

Notwithstanding the foregoing, and subject to the conditions below, the undersigned may transfer the Lock-Up Securities without the prior written consent of the Representative, provided, that: (1) in the case of any transfer pursuant to any of clauses (i)-(vii) below, the Representative receives a signed lock-up agreement for the balance of the Lock-Up Period from each donee, trustee, distributee, or transferee, as the case may be; (2) in the case of any transfer pursuant to clauses (i)-(vi) below, such transfer shall not involve a disposition for value; (3) except in the case of gifts pursuant to clause (i) below, such transfers are not required to be reported with the Securities and Exchange Commission (“SEC”) on Form 4 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or with any Canadian Securities Regulators under National Instrument 55-104 – Insider Reporting Requirements and Exemptions (“NI 55-104”); and (4) in the case of any transfer pursuant to clauses (i)-(vii), the undersigned does not otherwise voluntarily effect any public filing or report regarding any such transfer (other than a filing on a Form 5 in accordance with Section 16 of the Exchange Act, or any required insider report under NI 55-104 made after the expiration of the Lock-Up Period):

 

(i)as a bona fide gift or gifts;

 

 

 

(ii)upon death or by will, testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family (as defined below) of the undersigned;

 

(iii)to any immediate family member of the undersigned or to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this lock-up agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin);

 

(iv)as a distribution or other transfer to partners, members, shareholders or stockholders of the undersigned or under common control or management by entities that are affiliates of the undersigned;

 

(v)to the undersigned’s affiliates, as defined in Rule 405 under the Securities Act, or to any investment fund or other entity controlled or managed by the undersigned;

 

(vi)if the undersigned is a trust, to a trustor, trustee or beneficiary of the trust or to the estate of a trustor, trustee or beneficiary of such trust;

 

(vii)pursuant to a domestic order or negotiated divorce settlement; or

 

(viii)the withholding of Common Shares by, or surrender of Common Shares to, the Company pursuant to a “net” or “cashless” exercise or settlement feature to cover taxes due upon or the consideration required in connection with the exercise of securities issued under an equity incentive plan or share purchase plan of the Company, provided that if the undersigned is required to make a filing under the Exchange Act, or an insider report under NI 55-104, such filing shall include a footnote describing the purpose of the transaction.

 

Furthermore, no provision in this lock-up agreement shall be deemed to restrict or prohibit (1) the transfer of the undersigned’s Common Shares or any security convertible into or exercisable or exchangeable for Common Shares to the Company in connection with the termination of the undersigned’s employment with the Company or pursuant to contractual arrangements under which the Company has the option to repurchase such Common Shares, provided that, if the undersigned is required to file a report under the Exchange Act reporting a reduction in beneficial ownership of Common Shares during the Lock-Up Period, the undersigned shall clearly indicate in the footnotes thereto that the filing relates to termination of the undersigned’s employment, and no other public announcement shall be made voluntarily in connection with such transfer (other than a filing on a Form 5 made after the expiration of the Lock-Up Period), (2) the establishment of any contract, instruction or trading plan pursuant to Rule 10b5-1 under the Exchange Act (“Rule 10b5-1”) for the transfer of Common Shares (a “Trading Plan”), provided that such Trading Plan does not provide for any transfers of Common Shares during the Lock-Up Period and provided, further, that to the extent a public announcement or filing under the Exchange Act or other public announcement, if any, is required by or on behalf of the undersigned or the Company regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of Common Shares may be made under such Trading Plan during the Lock-Up Period, (3) sales of Common Shares made pursuant to a Trading Plan that has been entered into and a copy of which has been provided to the Representative by the undersigned prior to the date of this lock-up agreement; provided that if the undersigned reports any such sales on a Form 4 filed with the SEC pursuant to Section 16 of the Exchange Act, the undersigned shall cause such Form 4 to include a statement that such transfer was effected pursuant to a Trading Plan meeting the requirements of Rule 10b5-1, (4) the exercise, vesting or settlement, as applicable, by the undersigned of any option to purchase any Common Shares or other equity awards pursuant to any equity incentive plan or share purchase plan of the Company; provided, that the underlying Common Shares shall continue to be subject to the restrictions on transfer set forth in this lock-up agreement, (5) the transfer of Common Shares or any security convertible into or exercisable or exchangeable for Common Shares pursuant to a bona fide third-party take-over bid, tender offer for securities of the Company, merger, amalgamation, arrangement, consolidation or other similar transaction that is approved by the board of directors of the Company, made to all holders of Common Shares and involving a change of control (as defined below), provided that all of the undersigned’s Lock-Up Securities that are not so transferred, sold, tendered or otherwise disposed of remain subject to this lock-up agreement, and provided further that it shall be a condition of the transfer that if the take-over bid, tender offer, merger, amalgamation, arrangement, consolidation or other such transaction is not completed, the undersigned’s Lock-Up Securities shall remain subject to the restrictions herein. For purposes of this lock-up agreement, “change of control” means any bona fide third-party take-over bid, tender offer, merger, amalgamation, arrangement, consolidation or other similar transaction, in one transaction or a series of related transactions, the result of which is that any “person” (as defined in Section 13(d)(3) of the Exchange Act), or group of affiliated persons, other than the Company, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of 50% or more of the total voting power of the voting shares of the Company (or the surviving entity). The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the Lock-Up Securities except in compliance with the foregoing restrictions.

 

 

 

This lock-up agreement shall automatically terminate and be of no further effect upon the earliest to occur, if any, of the following: (i) prior to the execution of the Underwriting Agreement, upon such date the Company, on the one hand, or the Representative, on the other hand, notify the other in writing that it or they do not intend to proceed with the Offering; (ii) the Underwriting Agreement is not executed before November 15, 2026, or (iii) upon the termination of the Underwriting Agreement (other than the provisions thereof that survive termination) in accordance with the terms thereof prior to payment for and delivery of the Common Shares to be sold thereunder.

 

The undersigned acknowledges and agrees that, although the Representative may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Offering, the Representative is not making a recommendation to you to participate in the Offering, enter into this lock-up agreement, or sell any Common Shares at the price determined in the Offering, and nothing set forth in such disclosures is intended to suggest that the Representative is making such a recommendation.

 

This lock-up agreement shall be governed by, and construed in accordance with, the internal laws of the State of New York, and may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

[SIGNATURE PAGE FOLLOWS]

 

 

 

  Very truly yours,
   
   
  Name of Security Holder (Print exact name)
   
  By:  
    Signature
   
   
  If not signing in an individual capacity:
   
   
  Name of Authorized Signatory (Print)
   
   
  Title of Authorized Signatory (Print)

 

(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)

 

 

Filing Exhibits & Attachments

2 documents

Keep reading